. 2020 Mar;8(1).
doi: 10.3390/medsci8010018.

Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments

Ugo Testa 1 Germana Castelli 1 Elvira Pelosi 1 
  • PMID: 32210163
  •     531 References
  •     5 citations


Breast cancer is the most commonly occurring cancer in women. There were over two-million new cases in world in 2018. It is the second leading cause of death from cancer in western countries. At the molecular level, breast cancer is a heterogeneous disease, which is characterized by high genomic instability evidenced by somatic gene mutations, copy number alterations, and chromosome structural rearrangements. The genomic instability is caused by defects in DNA damage repair, transcription, DNA replication, telomere maintenance and mitotic chromosome segregation. According to molecular features, breast cancers are subdivided in subtypes, according to activation of hormone receptors (estrogen receptor and progesterone receptor), of human epidermal growth factors receptor 2 (HER2), and or BRCA mutations. In-depth analyses of the molecular features of primary and metastatic breast cancer have shown the great heterogeneity of genetic alterations and their clonal evolution during disease development. These studies have contributed to identify a repertoire of numerous disease-causing genes that are altered through different mutational processes. While early-stage breast cancer is a curable disease in about 70% of patients, advanced breast cancer is largely incurable. However, molecular studies have contributed to develop new therapeutic approaches targeting HER2, CDK4/6, PI3K, or involving poly(ADP-ribose) polymerase inhibitors for BRCA mutation carriers and immunotherapy.

Keywords: biomarkers; breast cancer; cancer; cancer genomics; target therapy.

PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α.
Lauren M Thorpe, Jennifer M Spangle, +4 authors, Jean J Zhao.
Proc Natl Acad Sci U S A, 2017 Jun 21; 114(27). PMID: 28630349    Free PMC article.
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.
Kevin H Kensler, Meredith M Regan, +10 authors, Rulla M Tamimi.
Breast Cancer Res, 2019 Feb 24; 21(1). PMID: 30795773    Free PMC article.
FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer.
M Oliveira, C Saura, +13 authors, S J Isakoff.
Ann Oncol, 2019 May 31; 30(8). PMID: 31147675
Highly Cited.
HER2 Overexpression Triggers an IL1α Proinflammatory Circuit to Drive Tumorigenesis and Promote Chemotherapy Resistance.
Shou Liu, Ji Shin Lee, +6 authors, Hexin Chen.
Cancer Res, 2018 Feb 01; 78(8). PMID: 29382706    Free PMC article.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
Shanu Modi, Cristina Saura, +23 authors, DESTINY-Breast01 Investigators.
N Engl J Med, 2019 Dec 12; 382(7). PMID: 31825192    Free PMC article.
Highly Cited.
Ligand-binding Domain-activating Mutations of ESR1 Rewire Cellular Metabolism of Breast Cancer Cells.
Lotem Zinger, Keren Merenbakh-Lamin, +7 authors, Ido Wolf.
Clin Cancer Res, 2019 Feb 09; 25(9). PMID: 30733228
Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer.
Jinani Jayasekera, Clyde B Schechter, +17 authors, CISNET-BOLD Collaborative Group.
J Natl Cancer Inst, 2018 Sep 22; 110(12). PMID: 30239794    Free PMC article.
Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis.
Md Kamrul Hasan, George F Widhopf, +5 authors, Thomas J Kipps.
NPJ Breast Cancer, 2019 Nov 02; 5. PMID: 31667337    Free PMC article.
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer.
Xiaoyong Fu, Resel Pereira, +21 authors, Rachel Schiff.
Proc Natl Acad Sci U S A, 2019 Dec 13;. PMID: 31826955    Free PMC article.
The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis.
Tamara Utermark, Trisha Rao, +7 authors, Jean J Zhao.
Genes Dev, 2012 Jul 18; 26(14). PMID: 22802530    Free PMC article.
p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value.
Angela Santoro, Thalia Vlachou, +16 authors, Pier Giuseppe Pelicci.
Cell Rep, 2019 Jan 17; 26(3). PMID: 30650356    Free PMC article.
Mammary-Stem-Cell-Based Somatic Mouse Models Reveal Breast Cancer Drivers Causing Cell Fate Dysregulation.
Zheng Zhang, John R Christin, +3 authors, Wenjun Guo.
Cell Rep, 2016 Sep 23; 16(12). PMID: 27653681    Free PMC article.
Activation of rapid oestrogen signalling in aggressive human breast cancers.
Coralie Poulard, Isabelle Treilleux, +6 authors, Muriel Le Romancer.
EMBO Mol Med, 2012 Oct 16; 4(11). PMID: 23065768    Free PMC article.
High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer.
Kevin Grosselin, Adeline Durand, +14 authors, Annabelle Gérard.
Nat Genet, 2019 Jun 04; 51(6). PMID: 31152164
Highly Cited.
Early ctDNA dynamics as a surrogate for progression-free survival in advanced breast cancer in the BEECH trial.
S Hrebien, V Citi, +11 authors, N Turner.
Ann Oncol, 2019 Mar 13; 30(6). PMID: 30860573    Free PMC article.
Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment.
Ana C Garrido-Castro, Nancy U Lin, Kornelia Polyak.
Cancer Discov, 2019 Jan 27; 9(2). PMID: 30679171    Free PMC article.
Highly Cited. Review.
The landscape of cancer genes and mutational processes in breast cancer.
Philip J Stephens, Patrick S Tarpey, +60 authors, Michael R Stratton.
Nature, 2012 Jun 23; 486(7403). PMID: 22722201    Free PMC article.
Highly Cited.
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Sara M Tolaney, Hao Guo, +23 authors, Eric P Winer.
J Clin Oncol, 2019 Apr 03; 37(22). PMID: 30939096    Free PMC article.
Highly Cited.
LGR5 overexpression confers poor relapse-free survival in breast cancer patients.
Ming-Feng Hou, Po-Ming Chen, Pei-Yi Chu.
BMC Cancer, 2018 Feb 24; 18(1). PMID: 29471794    Free PMC article.
The Notch Pathway in Breast Cancer Progression.
Emmanuel N Kontomanolis, Sofia Kalagasidou, +4 authors, Zacharias N Fasoulakis.
ScientificWorldJournal, 2018 Aug 17; 2018. PMID: 30111989    Free PMC article.
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ivana Sestak, Richard Buus, +9 authors, Mitch Dowsett.
JAMA Oncol, 2018 Feb 17; 4(4). PMID: 29450494    Free PMC article.
Highly Cited.
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
Lawrence A Donehower, Thierry Soussi, +10 authors, David A Wheeler.
Cell Rep, 2019 Aug 01; 28(5). PMID: 31365877    Free PMC article.
Highly Cited.
Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.
Carsten Denkert, Cornelia Liedtke, Andrew Tutt, Gunter von Minckwitz.
Lancet, 2016 Dec 13; 389(10087). PMID: 27939063
Highly Cited. Review.
Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type.
Britta Weigelt, Felipe C Geyer, +3 authors, Jorge S Reis-Filho.
Mod Pathol, 2009 Jul 28; 22(11). PMID: 19633645
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.
F Montemurro, S Di Cosimo, G Arpino.
Ann Oncol, 2013 Aug 03; 24(11). PMID: 23908178
Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
Jeff C Liu, Veronique Voisin, +10 authors, Eldad Zacksenhaus.
EMBO Mol Med, 2014 Oct 22; 6(12). PMID: 25330770    Free PMC article.
Estrogen receptor signaling is reprogrammed during breast tumorigenesis.
David Chi, Hari Singhal, +11 authors, Myles Brown.
Proc Natl Acad Sci U S A, 2019 May 22; 116(23). PMID: 31110002    Free PMC article.
Breast tumor heterogeneity: cancer stem cells or clonal evolution?
Lauren L Campbell, Kornelia Polyak.
Cell Cycle, 2007 Sep 06; 6(19). PMID: 17786053
Highly Cited. Review.
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups.
Oscar M Rueda, Stephen-John Sammut, +21 authors, Christina Curtis.
Nature, 2019 Mar 15; 567(7748). PMID: 30867590    Free PMC article.
Highly Cited.
Stem cells in the human breast.
Ole William Petersen, Kornelia Polyak.
Cold Spring Harb Perspect Biol, 2010 May 11; 2(5). PMID: 20452965    Free PMC article.
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.
Xiaomei Zhang, Sofie Claerhout, +26 authors, Michael T Lewis.
Cancer Res, 2013 Jun 06; 73(15). PMID: 23737486    Free PMC article.
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.
Stefano Annunziato, Catrin Lutz, +18 authors, Jos Jonkers.
EMBO J, 2020 Jan 14; 39(5). PMID: 31930530    Free PMC article.
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.
S Loibl, I Majewski, +13 authors, J Baselga.
Ann Oncol, 2016 May 15; 27(8). PMID: 27177864    Free PMC article.
Highly Cited.
Genomic Characterization of Primary Invasive Lobular Breast Cancer.
Christine Desmedt, Gabriele Zoppoli, +25 authors, Christos Sotiriou.
J Clin Oncol, 2016 Mar 02; 34(16). PMID: 26926684
Highly Cited.
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial.
Dhivya R Sudhan, Luis J Schwarz, +12 authors, Carlos L Arteaga.
Clin Cancer Res, 2018 Oct 03; 25(2). PMID: 30274983    Free PMC article.
microRNA-143/145 loss induces Ras signaling to promote aggressive Pten-deficient basal-like breast cancer.
Sharon Wang, Jeff C Liu, +7 authors, Eldad Zacksenhaus.
JCI Insight, 2017 Aug 05; 2(15). PMID: 28768903    Free PMC article.
Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Maki Tanioka, Cheng Fan, +18 authors, Charles M Perou.
Clin Cancer Res, 2018 Jul 25; 24(21). PMID: 30037817    Free PMC article.
Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series.
Johan Vallon-Christersson, Jari Häkkinen, +12 authors, Johan Staaf.
Sci Rep, 2019 Aug 23; 9(1). PMID: 31434940    Free PMC article.
Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability.
David Sarrió, Gema Moreno-Bueno, +6 authors, José Palacios.
Int J Cancer, 2003 Jun 12; 106(2). PMID: 12800196
Complex landscapes of somatic rearrangement in human breast cancer genomes.
Philip J Stephens, David J McBride, +30 authors, Michael R Stratton.
Nature, 2009 Dec 25; 462(7276). PMID: 20033038    Free PMC article.
Highly Cited.
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer.
Leticia De Mattos-Arruda, Stephen-John Sammut, +31 authors, Carlos Caldas.
Cell Rep, 2019 May 30; 27(9). PMID: 31141692    Free PMC article.
Highly Cited.
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), S Darby, +13 authors, R Peto.
Lancet, 2011 Oct 25; 378(9804). PMID: 22019144    Free PMC article.
Highly Cited. Review.
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
Valerie M Jansen, Neil E Bhola, +16 authors, Carlos L Arteaga.
Cancer Res, 2017 Mar 03; 77(9). PMID: 28249908    Free PMC article.
Highly Cited.
Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.
Mariana Ferreira Leal, Ben P Haynes, +10 authors, Mitch Dowsett.
Clin Cancer Res, 2019 Sep 25; 25(24). PMID: 31548345
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Fabrice André, Eva Ciruelos, +18 authors, SOLAR-1 Study Group.
N Engl J Med, 2019 May 16; 380(20). PMID: 31091374
Highly Cited.
Immunological differences between primary and metastatic breast cancer.
B Szekely, V Bossuyt, +13 authors, L Pusztai.
Ann Oncol, 2018 Sep 12; 29(11). PMID: 30203045
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.
François Bertucci, Pascal Finetti, +6 authors, Steven van Laere.
Oncotarget, 2015 May 06; 6(15). PMID: 25940795    Free PMC article.
Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma.
Lan Cao, Ahmed Basudan, +12 authors, Jennifer M Atkinson.
Cancer Lett, 2019 Jun 24; 461. PMID: 31229512    Free PMC article.
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.
Shom Goel, Qi Wang, +15 authors, Jean J Zhao.
Cancer Cell, 2016 Mar 16; 29(3). PMID: 26977878    Free PMC article.
Highly Cited.
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.
Pedram Razavi, Matthew T Chang, +42 authors, José Baselga.
Cancer Cell, 2018 Sep 12; 34(3). PMID: 30205045    Free PMC article.
Highly Cited.
Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Michael Untch, Gunter von Minckwitz, +16 authors, GBG and the AGO-B Study Group.
J Clin Oncol, 2018 Mar 16; 36(13). PMID: 29543566
Modelling cancer in microfluidic human organs-on-chips.
Alexandra Sontheimer-Phelps, Bryan A Hassell, Donald E Ingber.
Nat Rev Cancer, 2019 Jan 17; 19(2). PMID: 30647431
Highly Cited. Review.
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
Linda Sofie Lindström, Eva Karlsson, +6 authors, Jonas Bergh.
J Clin Oncol, 2012 Jun 20; 30(21). PMID: 22711854
Highly Cited.
Insight into the heterogeneity of breast cancer through next-generation sequencing.
Hege G Russnes, Nicholas Navin, James Hicks, Anne-Lise Borresen-Dale.
J Clin Invest, 2011 Oct 04; 121(10). PMID: 21965338    Free PMC article.
Highly Cited. Review.
Reconstruction of human mammary tissues in a mouse model.
David A Proia, Charlotte Kuperwasser.
Nat Protoc, 2007 Apr 05; 1(1). PMID: 17406234
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.
Zhiqiang Li, Pedram Razavi, +18 authors, Sarat Chandarlapaty.
Cancer Cell, 2018 Dec 12; 34(6). PMID: 30537512    Free PMC article.
Highly Cited.
Punctuated copy number evolution and clonal stasis in triple-negative breast cancer.
Ruli Gao, Alexander Davis, +10 authors, Nicholas E Navin.
Nat Genet, 2016 Aug 16; 48(10). PMID: 27526321    Free PMC article.
Highly Cited.
BRCA mutations in women with inflammatory breast cancer.
Angelica M Gutierrez Barrera, Tamer M Fouad, +7 authors, Banu K Arun.
Cancer, 2017 Oct 19; 124(3). PMID: 29044548    Free PMC article.
Progesterone induces adult mammary stem cell expansion.
Purna A Joshi, Hartland W Jackson, +6 authors, Rama Khokha.
Nature, 2010 May 07; 465(7299). PMID: 20445538
Highly Cited.
Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast.
C Marchiò, M Iravani, +13 authors, J S Reis-Filho.
J Pathol, 2008 May 20; 215(4). PMID: 18484683
Uncovering the genomic heterogeneity of multifocal breast cancer.
Christine Desmedt, Debora Fumagalli, +26 authors, Christos Sotiriou.
J Pathol, 2015 Apr 09; 236(4). PMID: 25850943    Free PMC article.
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27.
K Strasser-Weippl, G Sudan, +6 authors, P E Goss.
Eur J Cancer, 2017 Dec 24; 90. PMID: 29274617
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.
Sylvia Adams, Robert J Gray, +13 authors, Sunil S Badve.
J Clin Oncol, 2014 Jul 30; 32(27). PMID: 25071121    Free PMC article.
Highly Cited.
Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease.
Mathew Thomas, Erinn Downs Kelly, Jame Abraham, Megan Kruse.
Semin Oncol, 2019 Jun 27; 46(2). PMID: 31239068
Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Jeffrey S Ross, Laurie M Gay, +10 authors, Philip J Stephens.
Breast Cancer Res Treat, 2016 Jan 15; 155(2). PMID: 26762307
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
Stefano Annunziato, Julian R de Ruiter, +16 authors, Jos Jonkers.
Nat Commun, 2019 Jan 25; 10(1). PMID: 30674894    Free PMC article.
Six novel immunoglobulin genes as biomarkers for better prognosis in triple-negative breast cancer by gene co-expression network analysis.
Huan-Ming Hsu, Chi-Ming Chu, +7 authors, Yu-Tien Chang.
Sci Rep, 2019 Mar 16; 9(1). PMID: 30872752    Free PMC article.
Wnt and Neuregulin1/ErbB signalling extends 3D culture of hormone responsive mammary organoids.
Thierry Jardé, Bethan Lloyd-Lewis, +7 authors, Trevor C Dale.
Nat Commun, 2016 Oct 27; 7. PMID: 27782124    Free PMC article.
Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers.
Sarah Naomi Olsen, Ania Wronski, +13 authors, Karen Cichowski.
Cancer Discov, 2016 Dec 16; 7(2). PMID: 27974415    Free PMC article.
Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway.
Jie Liu, Juan Li, +11 authors, Peijun Liu.
Sci Rep, 2017 Feb 09; 7. PMID: 28169360    Free PMC article.
Lineage-Biased Stem Cells Maintain Estrogen-Receptor-Positive and -Negative Mouse Mammary Luminal Lineages.
Chunhui Wang, John R Christin, Maja H Oktay, Wenjun Guo.
Cell Rep, 2017 Mar 23; 18(12). PMID: 28329676    Free PMC article.
Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype.
M V Giuli, E Giuliani, +2 authors, S Checquolo.
J Oncol, 2019 Aug 06; 2019. PMID: 31379945    Free PMC article.
Applications of patient-derived tumor xenograft models and tumor organoids.
Go J Yoshida.
J Hematol Oncol, 2020 Jan 09; 13(1). PMID: 31910904    Free PMC article.
Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast.
Yunn-Yi Chen, Eun-Sil Shelley Hwang, +11 authors, Frederic M Waldman.
Am J Surg Pathol, 2009 Aug 25; 33(11). PMID: 19701073    Free PMC article.
Immune Infiltration in Invasive Lobular Breast Cancer.
Christine Desmedt, Roberto Salgado, +21 authors, Christos Sotiriou.
J Natl Cancer Inst, 2018 Feb 23; 110(7). PMID: 29471435    Free PMC article.
Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial.
Otto Metzger Filho, Anita Giobbie-Hurder, +12 authors, Aron Goldhirsch.
J Clin Oncol, 2015 Jul 29; 33(25). PMID: 26215945    Free PMC article.
Notch3 Maintains Luminal Phenotype and Suppresses Tumorigenesis and Metastasis of Breast Cancer via Trans-Activating Estrogen Receptor-α.
Xiao-Wei Dou, Yuan-Ke Liang, +10 authors, Guo-Jun Zhang.
Theranostics, 2017 Nov 08; 7(16). PMID: 29109797    Free PMC article.
Comparison of 2D- and 3D-culture models as drug-testing platforms in breast cancer.
Yoshinori Imamura, Toru Mukohara, +8 authors, Hironobu Minami.
Oncol Rep, 2015 Jan 31; 33(4). PMID: 25634491
Highly Cited.
Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer.
Arielle J Medford, Taronish D Dubash, +19 authors, Aditya Bardia.
NPJ Precis Oncol, 2019 Jul 26; 3. PMID: 31341951    Free PMC article.
Endocrine differentiation in mucoid carcinoma of the breast.
C Capella, V Eusebi, B Mann, J G Azzopardi.
Histopathology, 1980 Nov 01; 4(6). PMID: 6254868
A method for quantifying normal human mammary epithelial stem cells with in vivo regenerative ability.
Peter Eirew, John Stingl, +4 authors, Connie J Eaves.
Nat Med, 2008 Nov 26; 14(12). PMID: 19029987
Highly Cited.
The Genomic Landscape of Male Breast Cancers.
Salvatore Piscuoglio, Charlotte K Y Ng, +19 authors, Jorge S Reis-Filho.
Clin Cancer Res, 2016 Mar 11; 22(16). PMID: 26960396    Free PMC article.
PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer.
Mellissa J Nixon, Luigi Formisano, +12 authors, Justin M Balko.
NPJ Breast Cancer, 2019 Sep 26; 5. PMID: 31552290    Free PMC article.
Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis.
Peter Savas, Balaji Virassamy, +23 authors, Sherene Loi.
Nat Med, 2018 Jun 27; 24(7). PMID: 29942092
Highly Cited.
PI3K inhibition to overcome endocrine resistance in breast cancer.
Niamh M Keegan, Jack P Gleeson, Bryan T Hennessy, Patrick G Morris.
Expert Opin Investig Drugs, 2017 Dec 19; 27(1). PMID: 29252036
LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy.
Chia-Chen Liu, Julie Prior, David Piwnica-Worms, Guojun Bu.
Proc Natl Acad Sci U S A, 2010 Mar 03; 107(11). PMID: 20194742    Free PMC article.
Consistent and reproducible cultures of large-scale 3D mammary epithelial structures using an accessible bioprinting platform.
John A Reid, Peter A Mollica, Robert D Bruno, Patrick C Sachs.
Breast Cancer Res, 2018 Oct 12; 20(1). PMID: 30305139    Free PMC article.
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Mitch Dowsett, Ivana Sestak, +5 authors, Jack Cuzick.
J Clin Oncol, 2018 Apr 21; 36(19). PMID: 29676944    Free PMC article.
Phenotypic and functional characterisation of the luminal cell hierarchy of the mammary gland.
Mona Shehata, Andrew Teschendorff, +8 authors, John Stingl.
Breast Cancer Res, 2012 Oct 24; 14(5). PMID: 23088371    Free PMC article.
Highly Cited.
Oncogenic PIK3CA mutations in lobular breast cancer progression.
Matthias Christgen, Monika Noskowicz, +6 authors, Ulrich Lehmann.
Genes Chromosomes Cancer, 2012 Sep 22; 52(1). PMID: 22997091
Wnt signaling in triple negative breast cancer is associated with metastasis.
Nandini Dey, Benjamin G Barwick, +11 authors, Brian R Leyland-Jones.
BMC Cancer, 2013 Nov 12; 13. PMID: 24209998    Free PMC article.
Highly Cited.
Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis.
Celine Lefebvre, Thomas Bachelot, +31 authors, Fabrice André.
PLoS Med, 2016 Dec 28; 13(12). PMID: 28027327    Free PMC article.
Highly Cited.
In situ identification of bipotent stem cells in the mammary gland.
Anne C Rios, Nai Yang Fu, Geoffrey J Lindeman, Jane E Visvader.
Nature, 2014 Jan 28; 506(7488). PMID: 24463516
Highly Cited.
Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer.
Yumeng Wang, Xiaoyan Xu, +20 authors, Han Liang.
Cell Rep, 2018 Nov 01; 25(5). PMID: 30380420    Free PMC article.
Highly Cited.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
Genome doubling shapes the evolution and prognosis of advanced cancers.
Craig M Bielski, Ahmet Zehir, +17 authors, Barry S Taylor.
Nat Genet, 2018 Jul 18; 50(8). PMID: 30013179    Free PMC article.
Highly Cited.
PIK3CA mutations in in situ and invasive breast carcinomas.
Alexander Miron, Maria Varadi, +13 authors, Kornelia Polyak.
Cancer Res, 2010 Jun 17; 70(14). PMID: 20551053    Free PMC article.
Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast.
Yeji An, Jessica R Adams, +19 authors, Sean E Egan.
Cell Rep, 2018 Oct 18; 25(3). PMID: 30332649    Free PMC article.
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
Hermela Shimelis, Holly LaDuca, +26 authors, Fergus J Couch.
J Natl Cancer Inst, 2018 Aug 14; 110(8). PMID: 30099541    Free PMC article.
Highly Cited.
Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
Wei Yang, Sarah R Hosford, +13 authors, Todd W Miller.
Clin Cancer Res, 2016 Jan 07; 22(9). PMID: 26733612    Free PMC article.
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study.
Shanu Modi, Haeseong Park, +14 authors, Shunji Takahashi.
J Clin Oncol, 2020 Feb 15; 38(17). PMID: 32058843    Free PMC article.
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
Yi-Zhou Jiang, Ding Ma, +40 authors, Zhi-Ming Shao.
Cancer Cell, 2019 Mar 12; 35(3). PMID: 30853353
Highly Cited.
Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Jing Yang, Ji Nie, +3 authors, Xiawei Wei.
Mol Cancer, 2019 Feb 21; 18(1). PMID: 30782187    Free PMC article.
Highly Cited. Review.
Metaplastic Breast Cancer: Molecular Typing and Identification of Potential Targeted Therapies at a Single Institution.
Jessica Edenfield, Christine Schammel, +2 authors, W Jeff Edenfield.
Clin Breast Cancer, 2016 Aug 29; 17(1). PMID: 27568101
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Matthew P Goetz, Masakazu Toi, +15 authors, Angelo Di Leo.
J Clin Oncol, 2017 Oct 03; 35(32). PMID: 28968163
Highly Cited.
Scalable Fabrication of Stretchable, Dual Channel, Microfluidic Organ Chips.
Richard Novak, Meredyth Didier, +8 authors, Donald E Ingber.
J Vis Exp, 2018 Nov 06; (140). PMID: 30394380    Free PMC article.
Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Florence Coussy, Marion Lavigne, +19 authors, Elisabetta Marangoni.
Theranostics, 2020 Feb 12; 10(4). PMID: 32042320    Free PMC article.
Basal but not luminal mammary epithelial cells require PI3K/mTOR signaling for Ras-driven overgrowth.
Kristin A Plichta, Jessica L Mathers, +2 authors, Edward J Gunther.
Cancer Res, 2012 Sep 27; 72(22). PMID: 23010075    Free PMC article.
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
Nicholas C Turner, Dennis J Slamon, +16 authors, Massimo Cristofanilli.
N Engl J Med, 2018 Oct 23; 379(20). PMID: 30345905
Highly Cited.
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.
Bernard Pereira, Suet-Feung Chin, +31 authors, Carlos Caldas.
Nat Commun, 2016 May 11; 7. PMID: 27161491    Free PMC article.
Highly Cited.
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells.
Michelangelo Cordenonsi, Francesca Zanconato, +12 authors, Stefano Piccolo.
Cell, 2011 Nov 15; 147(4). PMID: 22078877
Highly Cited.
Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4.
E Neuman, M H Ladha, +8 authors, M E Ewen.
Mol Cell Biol, 1997 Sep 01; 17(9). PMID: 9271411    Free PMC article.
Highly Cited.
Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers.
Yoon-Sim Yap, Angad P Singh, +7 authors, Derek Y Chiang.
NPJ Breast Cancer, 2018 Aug 01; 4. PMID: 30062102    Free PMC article.
Mutational processes molding the genomes of 21 breast cancers.
Serena Nik-Zainal, Ludmil B Alexandrov, +51 authors, Breast Cancer Working Group of the International Cancer Genome Consortium.
Cell, 2012 May 23; 149(5). PMID: 22608084    Free PMC article.
Highly Cited.
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer.
Funda Meric-Bernstam, Xiaofeng Zheng, +18 authors, Ken Chen.
JCO Precis Oncol, 2018 Jul 24; 2018. PMID: 30035249    Free PMC article.
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
Steven J Isakoff, Jeffrey A Engelman, +5 authors, Joan S Brugge.
Cancer Res, 2005 Dec 03; 65(23). PMID: 16322248
Highly Cited.
Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter.
Luigi Cicatiello, Raffaele Addeo, +11 authors, Alessandro Weisz.
Mol Cell Biol, 2004 Jul 30; 24(16). PMID: 15282324    Free PMC article.
Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology.
Amy E McCart Reed, Jamie R Kutasovic, +20 authors, Peter T Simpson.
J Pathol, 2018 Jan 19; 244(4). PMID: 29344954    Free PMC article.
Estrogen receptor alpha mediates progestin-induced mammary tumor growth by interacting with progesterone receptors at the cyclin D1/MYC promoters.
Sebastián Giulianelli, José P Vaqué, +9 authors, Claudia Lanari.
Cancer Res, 2012 Mar 08; 72(9). PMID: 22396492
A high AR:ERα or PDEF:ERα ratio predicts a sub-optimal response to tamoxifen therapy in ERα-positive breast cancer.
Lu Cao, Guomin Xiang, +6 authors, Yun Niu.
Cancer Chemother Pharmacol, 2019 Jul 13; 84(3). PMID: 31297554
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, +22 authors, Andrea L Richardson.
Clin Cancer Res, 2016 Mar 10; 22(15). PMID: 26957554    Free PMC article.
Highly Cited.
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.
Francisco E Vera-Badillo, Arnoud J Templeton, +7 authors, Eitan Amir.
J Natl Cancer Inst, 2013 Nov 26; 106(1). PMID: 24273215
Highly Cited. Systematic Review.
The genetic landscape of breast carcinomas with neuroendocrine differentiation.
Caterina Marchiò, Felipe C Geyer, +12 authors, Jorge S Reis-Filho.
J Pathol, 2016 Dec 08; 241(3). PMID: 27925203    Free PMC article.
Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
Shaveta Vinayak, Sara M Tolaney, +17 authors, Melinda L Telli.
JAMA Oncol, 2019 Jun 14;. PMID: 31194225    Free PMC article.
Highly Cited.
Growth of human breast tissues from patient cells in 3D hydrogel scaffolds.
Ethan S Sokol, Daniel H Miller, +3 authors, Piyush B Gupta.
Breast Cancer Res, 2016 Mar 02; 18(1). PMID: 26926363    Free PMC article.
Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors.
Gianluca Lopez, Jole Costanza, +4 authors, Nicola Fusco.
Int J Mol Sci, 2019 Jan 30; 20(3). PMID: 30691046    Free PMC article.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Sibylle Loibl, Joyce O'Shaughnessy, +16 authors, Charles E Geyer.
Lancet Oncol, 2018 Mar 05; 19(4). PMID: 29501363
Highly Cited.
Towards personalized treatment for early stage HER2-positive breast cancer.
Kristina Goutsouliak, Jamunarani Veeraraghavan, +4 authors, Rachel Schiff.
Nat Rev Clin Oncol, 2019 Dec 15; 17(4). PMID: 31836877
Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.
Upasana Joneja, Semir Vranic, +7 authors, Zoran Gatalica.
J Clin Pathol, 2016 Aug 18; 70(3). PMID: 27531819    Free PMC article.
A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses.
Guillermo Prado-Vázquez, Angelo Gámez-Pozo, +11 authors, Juan Ángel Fresno Vara.
Sci Rep, 2019 Feb 09; 9(1). PMID: 30733547    Free PMC article.
LGR5 acts as a target of miR-340-5p in the suppression of cell progression and drug resistance in breast cancer via Wnt/β-catenin pathway.
Shuai Shi, Xiao Chen, +5 authors, Libo Zou.
Gene, 2018 Oct 10; 683. PMID: 30300682
Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.
Elisabetta Marangoni, Cécile Laurent, +22 authors, Fabien Reyal.
Clin Cancer Res, 2018 Feb 22; 24(11). PMID: 29463559
Establishing estrogen-responsive mouse mammary organoids from single Lgr5+ cells.
Lixing Zhang, Mohammad Adileh, +6 authors, Richard Kolesnick.
Cell Signal, 2016 Nov 05; 29. PMID: 27511963    Free PMC article.
Clinical utility of gene-expression signatures in early stage breast cancer.
Maryann Kwa, Andreas Makris, Francisco J Esteva.
Nat Rev Clin Oncol, 2017 Jun 01; 14(10). PMID: 28561071
Highly Cited. Review.
Control of mammary stem cell function by steroid hormone signalling.
Marie-Liesse Asselin-Labat, François Vaillant, +8 authors, Jane E Visvader.
Nature, 2010 Apr 13; 465(7299). PMID: 20383121
Highly Cited.
PTEN-mediated apical segregation of phosphoinositides controls epithelial morphogenesis through Cdc42.
Fernando Martin-Belmonte, Ama Gassama, +4 authors, Keith Mostov.
Cell, 2007 Jan 27; 128(2). PMID: 17254974    Free PMC article.
Highly Cited.
A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
P Nuciforo, T Pascual, +20 authors, E Holgado.
Ann Oncol, 2017 Oct 19; 29(1). PMID: 29045543
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.
Jennifer K Litton, Marion E Scoggins, +16 authors, Banu K Arun.
J Clin Oncol, 2019 Aug 29; 38(5). PMID: 31461380    Free PMC article.
Highly Cited.
A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer.
Benjamin T Spike, Dannielle D Engle, +3 authors, Geoffrey M Wahl.
Cell Stem Cell, 2012 Feb 07; 10(2). PMID: 22305568    Free PMC article.
Highly Cited.
3D Primary Culture Model to Study Human Mammary Development.
Daniel H Miller, Ethan S Sokol, Piyush B Gupta.
Methods Mol Biol, 2017 Jun 22; 1612. PMID: 28634940
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer.
Brian D Lehmann, Vandana G Abramson, +16 authors, Translational Breast Cancer Research Consortium.
Clin Cancer Res, 2019 Dec 12; 26(9). PMID: 31822498    Free PMC article.
Genomic characterization of metastatic breast cancers.
François Bertucci, Charlotte K Y Ng, +25 authors, Fabrice André.
Nature, 2019 May 24; 569(7757). PMID: 31118521
Highly Cited.
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Marie Colombe Agahozo, Anieta M Sieuwerts, +8 authors, Carolien H M van Deurzen.
Endocr Relat Cancer, 2019 Mar 08; 26(5). PMID: 30844755
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Jill M Spoerke, Steven Gendreau, +13 authors, Mark R Lackner.
Nat Commun, 2016 May 14; 7. PMID: 27174596    Free PMC article.
Highly Cited.
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
Dan R Robinson, Yi-Mi Wu, +22 authors, Arul M Chinnaiyan.
Nat Genet, 2013 Nov 05; 45(12). PMID: 24185510    Free PMC article.
Highly Cited.
Cancer statistics, 2018.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal.
CA Cancer J Clin, 2018 Jan 10; 68(1). PMID: 29313949
Highly Cited.
Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.
Ahmed Basudan, Nolan Priedigkeit, +16 authors, Steffi Oesterreich.
Mol Cancer Res, 2018 Oct 26; 17(2). PMID: 30355675    Free PMC article.
A new genome-driven integrated classification of breast cancer and its implications.
Sarah-Jane Dawson, Oscar M Rueda, Samuel Aparicio, Carlos Caldas.
EMBO J, 2013 Feb 12; 32(5). PMID: 23395906    Free PMC article.
Highly Cited. Review.
Wnt proteins are self-renewal factors for mammary stem cells and promote their long-term expansion in culture.
Yi Arial Zeng, Roel Nusse.
Cell Stem Cell, 2010 Jun 24; 6(6). PMID: 20569694    Free PMC article.
Highly Cited.
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Charlotte Fribbens, Ben O'Leary, +14 authors, Nicholas C Turner.
J Clin Oncol, 2016 Jun 09; 34(25). PMID: 27269946
Highly Cited.
Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions.
Steven A Roberts, Joan Sterling, +9 authors, Dmitry A Gordenin.
Mol Cell, 2012 May 23; 46(4). PMID: 22607975    Free PMC article.
Highly Cited.
Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant.
Pei-Yin Hsu, Victoria Shang Wu, +12 authors, Shiuan Chen.
Clin Cancer Res, 2017 Oct 29; 24(2). PMID: 29079660
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.
Johan Staaf, Dominik Glodzik, +18 authors, Serena Nik-Zainal.
Nat Med, 2019 Oct 02; 25(10). PMID: 31570822    Free PMC article.
Highly Cited.
Mixed micropapillary-ductal carcinomas of the breast: a genomic and immunohistochemical analysis of morphologically distinct components.
Caterina Marchiò, Marjan Iravani, +13 authors, Jorge S Reis-Filho.
J Pathol, 2009 May 30; 218(3). PMID: 19479727
Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.
Dimitrios Zardavas, Luc Te Marvelde, +29 authors, Sherene Loi.
J Clin Oncol, 2018 Feb 23; 36(10). PMID: 29470143
Integrative molecular profiling identifies a novel cluster of estrogen receptor-positive breast cancer in very young women.
Charny Park, Kyong-Ah Yoon, +8 authors, Eun Sook Lee.
Cancer Sci, 2019 Feb 28; 110(5). PMID: 30811755    Free PMC article.
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.
Debora Fumagalli, David Venet, +20 authors, Christos Sotiriou.
JAMA Oncol, 2016 Sep 30; 3(2). PMID: 27684533    Free PMC article.
Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.
Heather M Moore, Heidi M Savage, +7 authors, Timothy R Wilson.
Mol Cancer Ther, 2019 Sep 20; 19(1). PMID: 31534012
PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
Rita A Sakr, Britta Weigelt, +8 authors, Tari A King.
Clin Cancer Res, 2014 Mar 19; 20(9). PMID: 24634376    Free PMC article.
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Debu Tripathy, Seock-Ah Im, +23 authors, Yen-Shen Lu.
Lancet Oncol, 2018 May 29; 19(7). PMID: 29804902
Highly Cited.
Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
Richard Buus, Ivana Sestak, +9 authors, Jack Cuzick.
Clin Cancer Res, 2019 Oct 24; 26(3). PMID: 31641007
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
Seock-Ah Im, Yen-Shen Lu, +16 authors, Debu Tripathy.
N Engl J Med, 2019 Jun 06; 381(4). PMID: 31166679
Highly Cited.
Low PR in ER(+)/HER2(-) breast cancer: high rates of TP53 mutation and high SUV.
Sung Gwe Ahn, Chang Ik Yoon, +7 authors, Joon Jeong.
Endocr Relat Cancer, 2018 Nov 09; 26(2). PMID: 30407916    Free PMC article.
Genome remodelling in a basal-like breast cancer metastasis and xenograft.
Li Ding, Matthew J Ellis, +66 authors, Elaine R Mardis.
Nature, 2010 Apr 16; 464(7291). PMID: 20393555    Free PMC article.
Highly Cited.
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Brian D Lehmann, Bojana Jovanović, +6 authors, Jennifer A Pietenpol.
PLoS One, 2016 Jun 17; 11(6). PMID: 27310713    Free PMC article.
Highly Cited.
Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
Wilhem Leconet, Myriam Chentouf, +12 authors, Bruno Robert.
Clin Cancer Res, 2016 Dec 08; 23(11). PMID: 27923843
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Matthew D Burstein, Anna Tsimelzon, +10 authors, Powel H Brown.
Clin Cancer Res, 2014 Sep 12; 21(7). PMID: 25208879    Free PMC article.
Highly Cited.
Molecular portraits of human breast tumours.
C M Perou, T Sørlie, +15 authors, D Botstein.
Nature, 2000 Aug 30; 406(6797). PMID: 10963602
Highly Cited.
PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
Kai Wang, Qin Zhang, +10 authors, Peter Olson.
Clin Cancer Res, 2015 Jan 08; 21(6). PMID: 25564152
Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Serena Nik-Zainal, Helen Davies, +85 authors, Michael R Stratton.
Nature, 2016 May 03; 534(7605). PMID: 27135926    Free PMC article.
Highly Cited.
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Andrew Tutt, Holly Tovey, +35 authors, Judith M Bliss.
Nat Med, 2018 May 02; 24(5). PMID: 29713086    Free PMC article.
Highly Cited.
mRNA transcript quantification in archival samples using multiplexed, color-coded probes.
Patricia P Reis, Levi Waldron, +7 authors, Suzanne Kamel-Reid.
BMC Biotechnol, 2011 May 10; 11. PMID: 21549012    Free PMC article.
Highly Cited.
Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network.
Nature, 2012 Sep 25; 490(7418). PMID: 23000897    Free PMC article.
Highly Cited.
TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.
Utpal K Mukhopadhyay, Chetan C Oturkar, +16 authors, Gokul M Das.
J Natl Cancer Inst, 2019 Apr 17; 111(11). PMID: 30990221    Free PMC article.
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Luigi Formisano, Yao Lu, +28 authors, Carlos L Arteaga.
Nat Commun, 2019 Mar 28; 10(1). PMID: 30914635    Free PMC article.
Highly Cited.
Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Peter Kabos, Jessica Finlay-Schultz, +8 authors, Carol A Sartorius.
Breast Cancer Res Treat, 2012 Jul 24; 135(2). PMID: 22821401    Free PMC article.
Modeling Breast Cancer Using CRISPR-Cas9-Mediated Engineering of Human Breast Organoids.
Johanna F Dekkers, James R Whittle, +8 authors, Jane E Visvader.
J Natl Cancer Inst, 2019 Oct 08; 112(5). PMID: 31589320    Free PMC article.
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer.
Carlotta Costa, Ye Wang, +22 authors, Dejan Juric.
Cancer Discov, 2019 Oct 09; 10(1). PMID: 31594766
HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors.
Anneleen Daemen, Gerard Manning.
Breast Cancer Res, 2018 Feb 01; 20(1). PMID: 29382369    Free PMC article.
NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
François Bertucci, Charlotte Rypens, +17 authors, Steven Van Laere.
Mol Oncol, 2019 Dec 20; 14(3). PMID: 31854063    Free PMC article.
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
Charlotte K Y Ng, Salvatore Piscuoglio, +12 authors, Jorge S Reis-Filho.
Clin Cancer Res, 2017 Feb 06; 23(14). PMID: 28153863    Free PMC article.
Highly Cited.
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Aleix Prat, Joel S Parker, +5 authors, Charles M Perou.
Breast Cancer Res, 2010 Sep 04; 12(5). PMID: 20813035    Free PMC article.
Highly Cited.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
David Cameron, Martine J Piccart-Gebhart, +16 authors, Herceptin Adjuvant (HERA) Trial Study Team.
Lancet, 2017 Feb 22; 389(10075). PMID: 28215665    Free PMC article.
Highly Cited.
Heterogeneity of genomic profile in patients with HER2-positive breast cancer.
Bo Chen, Guochun Zhang, +15 authors, Ning Liao.
Endocr Relat Cancer, 2020 Jan 07; 27(3). PMID: 31905165
Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
C Van Berckelaer, C Rypens, +10 authors, L Dirix.
Breast Cancer Res, 2019 Feb 20; 21(1). PMID: 30777104    Free PMC article.
Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets.
Steven J Van Laere, Naoto T Ueno, +15 authors, François Bertucci.
Clin Cancer Res, 2013 Feb 12; 19(17). PMID: 23396049    Free PMC article.
Deregulating MYC in a model of HER2+ breast cancer mimics human intertumoral heterogeneity.
Tyler Risom, Xiaoyan Wang, +14 authors, Rosalie C Sears.
J Clin Invest, 2019 Nov 26; 130(1). PMID: 31763993    Free PMC article.
Tumor Organoids as a Pre-clinical Cancer Model for Drug Discovery.
Fleur Weeber, Salo N Ooft, Krijn K Dijkstra, Emile E Voest.
Cell Chem Biol, 2017 Aug 02; 24(9). PMID: 28757181
Highly Cited. Review.
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Mario Giuliano, Francesco Schettini, +16 authors, Daniele Generali.
Lancet Oncol, 2019 Sep 09; 20(10). PMID: 31494037
Systematic Review.
Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations.
Julie Massé, Caroline Truntzer, +11 authors, Gaëtan MacGrogan.
Mod Pathol, 2019 Dec 21; 33(6). PMID: 31857685
The molecular genetic make-up of male breast cancer.
Cathy B Moelans, Joep de Ligt, +22 authors, Paul J van Diest.
Endocr Relat Cancer, 2019 Jul 25; 26(10). PMID: 31340200    Free PMC article.
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
Fatima Cardoso, Laura J van't Veer, +32 authors, MINDACT Investigators.
N Engl J Med, 2016 Aug 25; 375(8). PMID: 27557300
Highly Cited.
The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer.
Ikbale El Ayachi, Iram Fatima, +19 authors, Gustavo A Miranda-Carboni.
Cancer Res, 2018 Dec 20; 79(5). PMID: 30563890    Free PMC article.
Patient-Derived Xenograft Models of Breast Cancer and Their Application.
Takahiko Murayama, Noriko Gotoh.
Cells, 2019 Jun 23; 8(6). PMID: 31226846    Free PMC article.
Identification of multipotent mammary stem cells by protein C receptor expression.
Daisong Wang, Cheguo Cai, +4 authors, Yi Arial Zeng.
Nature, 2014 Oct 21; 517(7532). PMID: 25327250
Highly Cited.
Role of RPL39 in Metaplastic Breast Cancer.
Bhuvanesh Dave, Daniel D Gonzalez, +14 authors, Jenny C Chang.
J Natl Cancer Inst, 2017 Jan 04; 109(6). PMID: 28040796    Free PMC article.
Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.
Marion Lavigne, Emmanuelle Menet, +10 authors, Anne Vincent-Salomon.
Mod Pathol, 2017 Sep 09; 31(1). PMID: 28884749
Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma.
Ju Youn Lee, Michail Schizas, +15 authors, Tari A King.
Clin Cancer Res, 2018 Sep 07; 25(2). PMID: 30185420    Free PMC article.
The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer.
Emmi Peurala, Peppi Koivunen, +2 authors, Arja Jukkola-Vuorinen.
Breast Cancer Res, 2013 Jan 23; 15(1). PMID: 23336272    Free PMC article.
Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.
Tamer M Fouad, Angelica M Gutierrez Barrera, +10 authors, Naoto T Ueno.
Lancet Oncol, 2017 Apr 04; 18(4). PMID: 28368261    Free PMC article.
CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
Stephan Bartels, Jana Lisa van Luttikhuizen, +8 authors, Hans Kreipe.
J Pathol, 2018 May 01; 245(3). PMID: 29708279
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis.
Francesco Schettini, Tomás Pascual, +25 authors, Aleix Prat.
Cancer Treat Rev, 2020 Jan 31; 84. PMID: 32000054    Free PMC article.
Systematic Review.
Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis.
Shuang Hao, Yuan-Yuan Zhao, +4 authors, Zhi-Ming Shao.
Sci Rep, 2019 Jan 24; 9(1). PMID: 30670771    Free PMC article.
Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.
Fresia Pareja, Pier Selenica, +9 authors, Hannah Y Wen.
Histopathology, 2019 Mar 08; 75(1). PMID: 30843622    Free PMC article.
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
Juan M Cejalvo, Eduardo Martínez de Dueñas, +24 authors, Aleix Prat.
Cancer Res, 2017 Mar 03; 77(9). PMID: 28249905    Free PMC article.
Highly Cited.
Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy.
Margaretha Rudas, Martina Lehnert, +13 authors, Austrian Breast and Colorectal Cancer Study Group.
Clin Cancer Res, 2008 Mar 19; 14(6). PMID: 18347178
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.
Joshua Z Drago, Luigi Formisano, +16 authors, Aditya Bardia.
Clin Cancer Res, 2019 Aug 03; 25(21). PMID: 31371343    Free PMC article.
Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation.
Jessie S Jeon, Simone Bersini, +4 authors, Roger D Kamm.
Proc Natl Acad Sci U S A, 2014 Dec 20; 112(1). PMID: 25524628    Free PMC article.
Highly Cited.
Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing.
Anna K Casasent, Aislyn Schalck, +7 authors, Nicholas E Navin.
Cell, 2018 Jan 09; 172(1-2). PMID: 29307488    Free PMC article.
Highly Cited.
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Mitch Dowsett, Jack Cuzick, +11 authors, Steven Shak.
J Clin Oncol, 2010 Mar 10; 28(11). PMID: 20212256
Highly Cited.
FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype.
Kevin M Levine, Nolan Priedigkeit, +17 authors, Steffi Oesterreich.
NPJ Breast Cancer, 2019 Jul 03; 5. PMID: 31263748    Free PMC article.
The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast.
Gary D Lewis, Yan Xing, +8 authors, Bin S Teh.
Breast J, 2019 Jul 20; 25(6). PMID: 31321854
Estrogen regulates Hippo signaling via GPER in breast cancer.
Xin Zhou, Shuyang Wang, +11 authors, Kun-Liang Guan.
J Clin Invest, 2015 Apr 22; 125(5). PMID: 25893606    Free PMC article.
Highly Cited.
Sequence analysis of mutations and translocations across breast cancer subtypes.
Shantanu Banerji, Kristian Cibulskis, +44 authors, Matthew Meyerson.
Nature, 2012 Jun 23; 486(7403). PMID: 22722202    Free PMC article.
Highly Cited.
Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.
Xu Liang, Sophie Vacher, +6 authors, Céline Callens.
Breast Cancer Res, 2018 Aug 09; 20(1). PMID: 30086764    Free PMC article.
G-Protein-Coupled Receptor 5 (LGR5) Overexpression Activates β-Catenin Signaling in Breast Cancer Cells via Protein Kinase A.
Zhishui Chen, Chengjun Xue.
Med Sci Monit Basic Res, 2019 Jan 22; 25. PMID: 30662060    Free PMC article.
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
R Wuerstlein, R Kates, +14 authors, WSG-PRIMe investigators in Germany, Austria, Switzerland.
Breast Cancer Res Treat, 2019 Feb 24; 175(2). PMID: 30796651    Free PMC article.
LobSig is a multigene predictor of outcome in invasive lobular carcinoma.
Amy E McCart Reed, Samir Lal, +18 authors, Peter T Simpson.
NPJ Breast Cancer, 2019 Jul 03; 5. PMID: 31263747    Free PMC article.
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2018 Jun 05; 379(2). PMID: 29860917    Free PMC article.
Highly Cited.
Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study.
J L Ethier, A Ocaña, +17 authors, M Martin.
Eur J Cancer, 2018 Mar 25; 94. PMID: 29573665
Mutation and immune profiling of metaplastic breast cancer: Correlation with survival.
Michelle Afkhami, Daniel Schmolze, +11 authors, Yuan Yuan.
PLoS One, 2019 Nov 07; 14(11). PMID: 31693690    Free PMC article.
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
Todd W Miller, Bryan T Hennessy, +7 authors, Carlos L Arteaga.
J Clin Invest, 2010 Jun 10; 120(7). PMID: 20530877    Free PMC article.
Highly Cited.
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Weiyi Toy, Yang Shen, +15 authors, Sarat Chandarlapaty.
Nat Genet, 2013 Nov 05; 45(12). PMID: 24185512    Free PMC article.
Highly Cited.
Integrated analyses of murine breast cancer models reveal critical parallels with human disease.
Jonathan P Rennhack, Briana To, +12 authors, Eran R Andrechek.
Nat Commun, 2019 Jul 25; 10(1). PMID: 31332182    Free PMC article.
BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
Henne Holstege, Hugo M Horlings, +5 authors, Jos Jonkers.
BMC Cancer, 2010 Dec 02; 10. PMID: 21118481    Free PMC article.
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.
Nicholas C Turner, Yuan Liu, +13 authors, Massimo Cristofanilli.
J Clin Oncol, 2019 Feb 27; 37(14). PMID: 30807234    Free PMC article.
Highly Cited.
E-cadherin loss induces targetable autocrine activation of growth factor signalling in lobular breast cancer.
Katy Teo, Laura Gómez-Cuadrado, +12 authors, Patrick W B Derksen.
Sci Rep, 2018 Oct 20; 8(1). PMID: 30337563    Free PMC article.
Derivation of a robust mouse mammary organoid system for studying tissue dynamics.
Paul R Jamieson, Johanna F Dekkers, +3 authors, Jane E Visvader.
Development, 2016 Dec 21; 144(6). PMID: 27993977
Characterization of organoid cultured human breast cancer.
Nadine Goldhammer, Jiyoung Kim, Vera Timmermans-Wielenga, Ole William Petersen.
Breast Cancer Res, 2019 Dec 13; 21(1). PMID: 31829259    Free PMC article.
HER2-positive breast cancer.
Sibylle Loibl, Luca Gianni.
Lancet, 2016 Dec 13; 389(10087). PMID: 27939064
Highly Cited. Review.
Emerging landscape of oncogenic signatures across human cancers.
Giovanni Ciriello, Martin L Miller, +3 authors, Chris Sander.
Nat Genet, 2013 Sep 28; 45(10). PMID: 24071851    Free PMC article.
Highly Cited.
PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
Sonia Pernas, Anna Petit, +13 authors, Aleix Prat.
Front Oncol, 2019 Aug 27; 9. PMID: 31448227    Free PMC article.
The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Omar Najim, Manon Huizing, +9 authors, Wiebren Tjalma.
Cancer Treat Res Commun, 2019 Mar 04; 19. PMID: 30826563
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis.
Marta Bonotto, Lorenzo Gerratana, +13 authors, Fabio Puglisi.
Breast, 2016 Nov 13; 31. PMID: 27837704
Early lineage segregation of multipotent embryonic mammary gland progenitors.
Aline Wuidart, Alejandro Sifrim, +9 authors, Cédric Blanpain.
Nat Cell Biol, 2018 May 23; 20(6). PMID: 29784918    Free PMC article.
Highly Cited.
A Spontaneous Aggressive ERα+ Mammary Tumor Model Is Driven by Kras Activation.
Katie M Campbell, Kathleen A O'Leary, +7 authors, Obi L Griffith.
Cell Rep, 2019 Aug 08; 28(6). PMID: 31390566    Free PMC article.
Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling.
Rachel Eyre, Denis G Alférez, +15 authors, Robert B Clarke.
Nat Commun, 2019 Nov 05; 10(1). PMID: 31676788    Free PMC article.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Miguel Martin, Frankie A Holmes, +32 authors, ExteNET Study Group.
Lancet Oncol, 2017 Nov 18; 18(12). PMID: 29146401
Highly Cited.
Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.
Rita S Mehta, William E Barlow, +9 authors, Gabriel N Hortobagyi.
N Engl J Med, 2019 Mar 28; 380(13). PMID: 30917258    Free PMC article.
Highly Cited.
Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer.
Juliet Richman, Mitch Dowsett.
Nat Rev Clin Oncol, 2018 Dec 20; 16(5). PMID: 30563978
Assembly and activation of the Hippo signalome by FAT1 tumor suppressor.
Daniel Martin, Maria S Degese, +18 authors, J Silvio Gutkind.
Nat Commun, 2018 Jul 10; 9(1). PMID: 29985391    Free PMC article.
Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations.
Jeffrey S Ross, Siraj M Ali, +10 authors, Massimo Cristofanilli.
Breast Cancer Res Treat, 2015 Oct 16; 154(1). PMID: 26458824
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Aleix Prat, Cristina Saura, +27 authors, Joaquín Gavilá.
Lancet Oncol, 2019 Dec 16; 21(1). PMID: 31838010
Collective Wisdom: Lobular Carcinoma of the Breast.
George W Sledge, Anees Chagpar, Charles Perou.
Am Soc Clin Oncol Educ Book, 2016 Jun 02; 35. PMID: 27249682
The Androgen Receptor in Breast Cancer.
Pia Giovannelli, Marzia Di Donato, +3 authors, Antimo Migliaccio.
Front Endocrinol (Lausanne), 2018 Sep 14; 9. PMID: 30210453    Free PMC article.
Highly Cited. Review.
Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.
Mohammad H Forouzanfar, Kyle J Foreman, +4 authors, Mohsen Naghavi.
Lancet, 2011 Sep 20; 378(9801). PMID: 21924486
Highly Cited. Review.
Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8+/PDL1+ Immune Infiltration in Inflammatory Breast Cancer Tumors.
Christopher A Hamm, Diarmuid Moran, +7 authors, Sarah Bacus.
Mol Cancer Ther, 2016 May 20; 15(7). PMID: 27196778
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry.
David J Dabbs, Stuart J Schnitt, +17 authors, Jorge S Reis-Filho.
Am J Surg Pathol, 2013 Jun 14; 37(7). PMID: 23759937
Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
Sherene Loi, Damien Drubay, +19 authors, Stefan Michiels.
J Clin Oncol, 2019 Jan 17; 37(7). PMID: 30650045    Free PMC article.
Highly Cited.
Gain of function in somatic TP53 mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages.
Michael Behring, Ana I Vazquez, +5 authors, Sadeep Shrestha.
Mol Genet Genomic Med, 2019 Oct 23; 7(12). PMID: 31637877    Free PMC article.
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Antonio Llombart-Cussac, Javier Cortés, +13 authors, Aleix Prat.
Lancet Oncol, 2017 Feb 28; 18(4). PMID: 28238593
Highly Cited.
Breast cancer precursors revisited: molecular features and progression pathways.
Maria A Lopez-Garcia, Felipe C Geyer, +2 authors, Jorge S Reis-Filho.
Histopathology, 2010 May 27; 57(2). PMID: 20500230
Highly Cited. Review.
A Non-canonical Role of YAP/TEAD Is Required for Activation of Estrogen-Regulated Enhancers in Breast Cancer.
Chi Zhu, Li Li, +10 authors, Zhijie Liu.
Mol Cell, 2019 Jul 16; 75(4). PMID: 31303470    Free PMC article.
PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours.
Shany Koren, Linsey Reavie, +9 authors, Mohamed Bentires-Alj.
Nature, 2015 Aug 13; 525(7567). PMID: 26266975
Highly Cited.
Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer.
Shen Zhao, Xi-Yu Liu, +4 authors, Yi-Zhou Jiang.
Theranostics, 2019 Aug 15; 9(17). PMID: 31410192    Free PMC article.
Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1.
Syed S Islam, Mohammed Uddin, +10 authors, Walid A Farhat.
EBioMedicine, 2019 May 16; 43. PMID: 31085100    Free PMC article.
The Genomic Landscape of Mucinous Breast Cancer.
Fresia Pareja, Ju Youn Lee, +20 authors, Britta Weigelt.
J Natl Cancer Inst, 2019 Jan 17; 111(7). PMID: 30649385    Free PMC article.
Highly Cited.
Barcoding reveals complex clonal dynamics of de novo transformed human mammary cells.
Long V Nguyen, Davide Pellacani, +16 authors, Connie J Eaves.
Nature, 2015 Dec 04; 528(7581). PMID: 26633636
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Hongchao Pan, Richard Gray, +9 authors, EBCTCG.
N Engl J Med, 2017 Nov 09; 377(19). PMID: 29117498    Free PMC article.
Highly Cited.
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer.
Maura N Dickler, Sara M Tolaney, +11 authors, José Baselga.
Clin Cancer Res, 2017 May 24; 23(17). PMID: 28533223    Free PMC article.
Highly Cited.
ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer.
Todd W Miller, Justin M Balko, +16 authors, Carlos L Arteaga.
Cancer Discov, 2011 Nov 04; 1(4). PMID: 22049316    Free PMC article.
Highly Cited.
Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression.
S Y Lin, W Xia, +5 authors, M C Hung.
Proc Natl Acad Sci U S A, 2000 Apr 12; 97(8). PMID: 10759547    Free PMC article.
Highly Cited.
TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells.
M Bartucci, R Dattilo, +14 authors, R De Maria.
Oncogene, 2014 Feb 18; 34(6). PMID: 24531710
Highly Cited.
Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer.
Swneke D Bailey, Kinjal Desai, +16 authors, Mathieu Lupien.
Nat Genet, 2016 Aug 30; 48(10). PMID: 27571262    Free PMC article.
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.
Neil Vasan, Pedram Razavi, +24 authors, José Baselga.
Science, 2019 Nov 09; 366(6466). PMID: 31699932    Free PMC article.
Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers.
Suriyan Ponnusamy, Sarah Asemota, +20 authors, Ramesh Narayanan.
iScience, 2019 Nov 08; 21. PMID: 31698248    Free PMC article.
Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.
Charissa Kim, Ruli Gao, +6 authors, Nicholas E Navin.
Cell, 2018 Apr 24; 173(4). PMID: 29681456    Free PMC article.
Highly Cited.
Supervised risk predictor of breast cancer based on intrinsic subtypes.
Joel S Parker, Michael Mullins, +17 authors, Philip S Bernard.
J Clin Oncol, 2009 Feb 11; 27(8). PMID: 19204204    Free PMC article.
Highly Cited.
Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.
Jing Zhai, Gabriel Giannini, +4 authors, Lily L Lai.
Hum Pathol, 2018 Dec 12; 86. PMID: 30537493
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast Cancer.
Linda S Lindström, Christina Yau, +19 authors, STO Trialists Group.
J Natl Cancer Inst, 2018 Jan 24; 110(7). PMID: 29361175    Free PMC article.
Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification.
Isabel Echavarria, Sara López-Tarruella, +19 authors, Miguel Martin.
Clin Cancer Res, 2018 Jan 31; 24(8). PMID: 29378733    Free PMC article.
Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.
Dejan Juric, Pau Castel, +25 authors, Maurizio Scaltriti.
Nature, 2014 Nov 20; 518(7538). PMID: 25409150    Free PMC article.
Highly Cited.
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice.
T C Wang, R D Cardiff, +3 authors, E V Schmidt.
Nature, 1994 Jun 23; 369(6482). PMID: 8208295
Highly Cited.
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
Pratyaksha Wirapati, Christos Sotiriou, +10 authors, Mauro Delorenzi.
Breast Cancer Res, 2008 Jul 30; 10(4). PMID: 18662380    Free PMC article.
Highly Cited.
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Jennifer Dunlap, Claudia Le, +5 authors, Megan L Troxell.
Breast Cancer Res Treat, 2009 May 07; 120(2). PMID: 19418217
Microscaled proteogenomic methods for precision oncology.
Shankha Satpathy, Eric J Jaehnig, +30 authors, Matthew J Ellis.
Nat Commun, 2020 Jan 29; 11(1). PMID: 31988290    Free PMC article.
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells.
Devon A Lawson, Nirav R Bhakta, +10 authors, Zena Werb.
Nature, 2015 Sep 30; 526(7571). PMID: 26416748    Free PMC article.
Highly Cited.
Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations.
Rinath Jeselsohn, Johann S Bergholz, +23 authors, Myles Brown.
Cancer Cell, 2018 Feb 14; 33(2). PMID: 29438694    Free PMC article.
Highly Cited.
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.
Y Bareche, D Venet, +4 authors, C Sotiriou.
Ann Oncol, 2018 Jan 25; 29(4). PMID: 29365031    Free PMC article.
Highly Cited.
Distinct stem cells contribute to mammary gland development and maintenance.
Alexandra Van Keymeulen, Ana Sofia Rocha, +6 authors, Cédric Blanpain.
Nature, 2011 Oct 11; 479(7372). PMID: 21983963
Highly Cited.
Novel mutations in neuroendocrine carcinoma of the breast: possible therapeutic targets.
Daphne Ang, Morgan Ballard, +8 authors, Megan L Troxell.
Appl Immunohistochem Mol Morphol, 2015 Feb 14; 23(2). PMID: 25679062
Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications.
Ana Godoy-Ortiz, Alfonso Sanchez-Muñoz, +4 authors, Emilio Alba.
Front Oncol, 2019 Nov 19; 9. PMID: 31737566    Free PMC article.
Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer.
M R Sheen, J D Marotti, +3 authors, S Fiering.
Oncogenesis, 2016 Nov 01; 5(10). PMID: 27797363    Free PMC article.
Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases.
Willemijne A M E Schrijver, Pier Selenica, +8 authors, Cathy B Moelans.
Cancer Res, 2018 Apr 05; 78(12). PMID: 29615433    Free PMC article.
Association Analysis of Somatic Copy Number Alteration Burden With Breast Cancer Survival.
Linfan Zhang, Nikta Feizi, Chen Chi, Pingzhao Hu.
Front Genet, 2018 Oct 20; 9. PMID: 30337938    Free PMC article.
Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer.
D Merino, T S Weber, +15 authors, S H Naik.
Nat Commun, 2019 Feb 17; 10(1). PMID: 30770823    Free PMC article.
Highly Cited.
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
Michalina Janiszewska, Lin Liu, +12 authors, Kornelia Polyak.
Nat Genet, 2015 Aug 25; 47(10). PMID: 26301495    Free PMC article.
Highly Cited.
Genomic profiling of metaplastic breast carcinomas reveals genetic heterogeneity and relationship to ductal carcinoma.
Gregor Krings, Yunn-Yi Chen.
Mod Pathol, 2018 Jun 28; 31(11). PMID: 29946183
Prevalence of germline variants in inflammatory breast cancer.
Huma Q Rana, Rosalba Sacca, +8 authors, Beth A Overmoyer.
Cancer, 2019 Apr 02; 125(13). PMID: 30933323
Lgr5 is a marker for fetal mammary stem cells, but is not essential for stem cell activity or tumorigenesis.
Christy L Trejo, Gidsela Luna, +2 authors, Geoffrey M Wahl.
NPJ Breast Cancer, 2017 Jun 27; 3. PMID: 28649656    Free PMC article.
Preclinical mouse cancer models: a maze of opportunities and challenges.
Chi-Ping Day, Glenn Merlino, Terry Van Dyke.
Cell, 2015 Sep 26; 163(1). PMID: 26406370    Free PMC article.
Highly Cited. Review.
Identification of frequent somatic mutations in inflammatory breast cancer.
Naoko Matsuda, Bora Lim, +8 authors, Naoto T Ueno.
Breast Cancer Res Treat, 2017 Mar 01; 163(2). PMID: 28243898
Breast cancer histologic subtypes show excess familial clustering.
N Lynn Henry, Lisa A Cannon-Albright.
Cancer, 2019 May 24; 125(18). PMID: 31120568    Free PMC article.
β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.
Felipe C Geyer, Magali Lacroix-Triki, +5 authors, Jorge S Reis-Filho.
Mod Pathol, 2010 Nov 16; 24(2). PMID: 21076461
Highly Cited.
Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer.
Sushil Kumar, Ratnesh Kumar Srivastav, +10 authors, Rumela Chakrabarti.
Oncogene, 2018 Nov 18; 38(12). PMID: 30442981    Free PMC article.
Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
Charlotte K Y Ng, Francois-Clement Bidard, +15 authors, Jorge S Reis-Filho.
Clin Cancer Res, 2017 Mar 30; 23(15). PMID: 28351929    Free PMC article.
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers.
Anthony Ferrari, Anne Vincent-Salomon, +40 authors, Gilles Thomas.
Nat Commun, 2016 Jul 14; 7. PMID: 27406316    Free PMC article.
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state.
Christine L Chaffer, Ines Brueckmann, +11 authors, Robert A Weinberg.
Proc Natl Acad Sci U S A, 2011 Apr 19; 108(19). PMID: 21498687    Free PMC article.
Highly Cited.
Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.
Matthew P Goetz, Krishna R Kalari, +25 authors, Judy C Boughey.
J Natl Cancer Inst, 2017 Apr 05; 109(7). PMID: 28376176    Free PMC article.
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium.
D J A Lobbezoo, R J W van Kampen, +10 authors, V C G Tjan-Heijnen.
Ann Oncol, 2015 Nov 19; 27(2). PMID: 26578730
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.
Mateus de Oliveira Taveira, Sheida Nabavi, +4 authors, Gerburg M Wulf.
J Cancer Res Clin Oncol, 2017 Mar 02; 143(7). PMID: 28247034    Free PMC article.
The emerging role of CDK4/6i in HER2-positive breast cancer.
Ciara C O'Sullivan, Vera J Suman, Matthew P Goetz.
Ther Adv Med Oncol, 2019 Dec 14; 11. PMID: 31832106    Free PMC article.
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy.
Sung-Bae Kim, In-Gu Do, +17 authors, Jungsil Ro.
Cancer Res Treat, 2019 Jun 06; 51(4). PMID: 31163957    Free PMC article.
Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases.
Yun Zhang, Shunbin Xiong, +9 authors, Guillermina Lozano.
Nat Commun, 2018 Sep 29; 9(1). PMID: 30262850    Free PMC article.
Regulation of estrogen rapid signaling through arginine methylation by PRMT1.
Muriel Le Romancer, Isabelle Treilleux, +6 authors, Laura Corbo.
Mol Cell, 2008 Jul 29; 31(2). PMID: 18657504
An Organotypic 3D Assay for Primary Human Mammary Epithelial Cells that Recapitulates Branching Morphogenesis.
Jelena R Linnemann, Lisa K Meixner, Haruko Miura, Christina H Scheel.
Methods Mol Biol, 2017 Jun 22; 1612. PMID: 28634939
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies.
Lindsay Angus, Marcel Smid, +17 authors, John W M Martens.
Nat Genet, 2019 Oct 02; 51(10). PMID: 31570896    Free PMC article.
Highly Cited.
HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1.
Yongguang Yang, Marissa Leonard, +6 authors, Xiaoting Zhang.
Cancer Res, 2017 Dec 01; 78(2). PMID: 29187405    Free PMC article.
Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy-results from the ACOSOG Z1041 (Alliance) trial.
R Lesurf, O L Griffith, +14 authors, E R Mardis.
Ann Oncol, 2017 Apr 30; 28(5). PMID: 28453704    Free PMC article.
Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Elizabeth L Kehr, Julie M Jorns, +7 authors, Megan L Troxell.
Hum Pathol, 2012 Jun 19; 43(12). PMID: 22705004
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
Brett Wallden, James Storhoff, +16 authors, Joel S Parker.
BMC Med Genomics, 2015 Aug 25; 8. PMID: 26297356    Free PMC article.
Highly Cited.
ESR1 mutations in metastatic lobular breast cancer patients.
Christine Desmedt, Julien Pingitore, +17 authors, Christos Sotiriou.
NPJ Breast Cancer, 2019 Mar 02; 5. PMID: 30820448    Free PMC article.
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations.
Elena Lopez-Knowles, Alex Pearson, +11 authors, Mitch Dowsett.
Br J Cancer, 2018 Dec 20; 120(2). PMID: 30563991    Free PMC article.
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
Chungyeul Kim, Gong Tang, +18 authors, Soonmyung Paik.
J Clin Oncol, 2011 Sep 29; 29(31). PMID: 21947828    Free PMC article.
Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
Andrey I Khramtsov, Galina F Khramtsova, +3 authors, Kathleen H Goss.
Am J Pathol, 2010 Apr 17; 176(6). PMID: 20395444    Free PMC article.
Highly Cited.
Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases.
Nolan Priedigkeit, Ryan J Hartmaier, +15 authors, Adrian V Lee.
JAMA Oncol, 2016 Dec 08; 3(5). PMID: 27926948    Free PMC article.
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
Chrysiis Michaloglou, Claire Crafter, +11 authors, Sabina C Cosulich.
Mol Cancer Ther, 2018 Feb 28; 17(5). PMID: 29483206    Free PMC article.
Highly Cited.
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.
Daniel Schramek, Andreas Leibbrandt, +13 authors, Josef M Penninger.
Nature, 2010 Oct 01; 468(7320). PMID: 20881962    Free PMC article.
Highly Cited.
Metastatic behavior of breast cancer subtypes.
Hagen Kennecke, Rinat Yerushalmi, +5 authors, Karen Gelmon.
J Clin Oncol, 2010 May 26; 28(20). PMID: 20498394
Highly Cited.
Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.
Jennifer A Schlichting, Amr S Soliman, +2 authors, Sofia D Merajver.
Breast Cancer Res Treat, 2012 Jun 27; 134(3). PMID: 22733221    Free PMC article.
The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells.
Angelo Cicalese, Giuseppina Bonizzi, +7 authors, Pier Giuseppe Pelicci.
Cell, 2009 Sep 22; 138(6). PMID: 19766563
Highly Cited.
Single-Cell Transcriptomes Distinguish Stem Cell State Changes and Lineage Specification Programs in Early Mammary Gland Development.
Rajshekhar R Giraddi, Chi-Yeh Chung, +14 authors, Benjamin T Spike.
Cell Rep, 2018 Aug 09; 24(6). PMID: 30089273    Free PMC article.
Neuroendocrine Tumors of the Breast.
Lauren Elizabeth Rosen, Paolo Gattuso.
Arch Pathol Lab Med, 2017 Oct 27; 141(11). PMID: 29072945
Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
Bradley A Hancock, Yu-Hsiang Chen, +14 authors, Milan Radovich.
Breast Cancer Res, 2019 Aug 07; 21(1). PMID: 31383035    Free PMC article.
Neratinib: Inching Up on the Cure Rate of HER2+ Breast Cancer?
Nisha Unni, Dhivya R Sudhan, Carlos L Arteaga.
Clin Cancer Res, 2018 May 29; 24(15). PMID: 29802101
High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.
Cecilia Ahlin, Claudia Lundgren, +3 authors, M -L Fjällskog.
Breast Cancer Res Treat, 2017 May 22; 164(3). PMID: 28528450    Free PMC article.
The prognostic effects of somatic mutations in ER-positive breast cancer.
Obi L Griffith, Nicholas C Spies, +30 authors, Matthew J Ellis.
Nat Commun, 2018 Sep 06; 9(1). PMID: 30181556    Free PMC article.
Lgr6 labels a rare population of mammary gland progenitor cells that are able to originate luminal mammary tumours.
Leander Blaas, Fabio Pucci, +16 authors, Axel Behrens.
Nat Cell Biol, 2016 Nov 01; 18(12). PMID: 27798604    Free PMC article.
Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer.
Ivana Sestak, Yi Zhang, +4 authors, Dennis Sgroi.
Clin Cancer Res, 2016 Jun 03; 22(20). PMID: 27252417
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
José Baselga, Seock-Ah Im, +22 authors, Mario Campone.
Lancet Oncol, 2017 Jun 04; 18(7). PMID: 28576675    Free PMC article.
Highly Cited.
Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer.
David Endesfelder, Rebecca Burrell, +6 authors, Maik Kschischo.
Cancer Res, 2014 Jun 28; 74(17). PMID: 24970479    Free PMC article.
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells.
Jean J Zhao, Zhenning Liu, +3 authors, Thomas M Roberts.
Proc Natl Acad Sci U S A, 2005 Dec 13; 102(51). PMID: 16339315    Free PMC article.
Highly Cited.
Developmental stage and time dictate the fate of Wnt/β-catenin-responsive stem cells in the mammary gland.
Renée van Amerongen, Angela N Bowman, Roel Nusse.
Cell Stem Cell, 2012 Aug 07; 11(3). PMID: 22863533
Highly Cited.
FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer.
Suparna Wedam, Lola Fashoyin-Aje, +7 authors, Julia A Beaver.
Clin Cancer Res, 2019 Oct 28; 26(6). PMID: 31649043
A Role for the WNT Co-Receptor LRP6 in Pathogenesis and Therapy of Epithelial Cancers.
Jennifer Raisch, Anthony Côté-Biron, Nathalie Rivard.
Cancers (Basel), 2019 Aug 16; 11(8). PMID: 31412666    Free PMC article.
Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.
Rina Hui, Alex Pearson, +20 authors, Giuseppe Curigliano.
Clin Cancer Res, 2019 Oct 18; 26(2). PMID: 31619444
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Carsten Denkert, Gunter von Minckwitz, +24 authors, Sibylle Loibl.
Lancet Oncol, 2017 Dec 14; 19(1). PMID: 29233559
Highly Cited.
A Four-gene Decision Tree Signature Classification of Triple-negative Breast Cancer: Implications for Targeted Therapeutics.
Jelmar Quist, Hasan Mirza, +5 authors, Anita Grigoriadis.
Mol Cancer Ther, 2018 Oct 12; 18(1). PMID: 30305342    Free PMC article.
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
N C Turner, E Alarcón, +20 authors, M Oliveira.
Ann Oncol, 2019 Mar 13; 30(5). PMID: 30860570    Free PMC article.
Highly Cited.
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
Hope S Rugo, R Bryan Rumble, +13 authors, Harold J Burstein.
J Clin Oncol, 2016 May 25; 34(25). PMID: 27217461
Highly Cited.
Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
K Nones, J Johnson, +32 authors, P T Simpson.
Ann Oncol, 2019 May 16; 30(7). PMID: 31090900    Free PMC article.
Microfluidic organs-on-chips.
Sangeeta N Bhatia, Donald E Ingber.
Nat Biotechnol, 2014 Aug 06; 32(8). PMID: 25093883
Highly Cited.
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer.
Sara A Hurvitz, Miguel Martin, +16 authors, Dennis J Slamon.
Clin Cancer Res, 2019 Oct 17; 26(3). PMID: 31615937    Free PMC article.
'Omics Approaches to Explore the Breast Cancer Landscape.
Joseph Parsons, Chiara Francavilla.
Front Cell Dev Biol, 2020 Feb 11; 7. PMID: 32039208    Free PMC article.
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression.
Marie-Anne Goyette, Stéphanie Duhamel, +12 authors, Jean-François Côté.
Cell Rep, 2018 May 03; 23(5). PMID: 29719259
Highly Cited.
Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
Roberto R Rosato, Daniel Dávila-González, +6 authors, Jenny C Chang.
Breast Cancer Res, 2018 Sep 07; 20(1). PMID: 30185216    Free PMC article.
A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Dong-Yu Wang, Deena M A Gendoo, +2 authors, Eldad Zacksenhaus.
Breast Cancer Res, 2019 Feb 02; 21(1). PMID: 30704524    Free PMC article.
Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma.
Angela B Ortiz, Diego Garcia, +3 authors, Paloma Martin.
PLoS One, 2017 Nov 16; 12(11). PMID: 29140993    Free PMC article.
Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.
Weiyi Toy, Hazel Weir, +17 authors, Sarat Chandarlapaty.
Cancer Discov, 2016 Dec 18; 7(3). PMID: 27986707    Free PMC article.
Highly Cited.
Mammary fibroblasts reduce apoptosis and speed estrogen-induced hyperplasia in an organotypic MCF7-derived duct model.
Molly M Morgan, Megan K Livingston, +4 authors, Brian P Johnson.
Sci Rep, 2018 May 10; 8(1). PMID: 29740030    Free PMC article.
Single-cell landscape in mammary epithelium reveals bipotent-like cells associated with breast cancer risk and outcome.
Weiyan Chen, Samuel J Morabito, +3 authors, Andrew E Teschendorff.
Commun Biol, 2019 Aug 21; 2. PMID: 31428694    Free PMC article.
The expression of β-catenin in different subtypes of breast cancer and its clinical significance.
Shuguang Li, Shanshan Li, Ying Sun, Li Li.
Tumour Biol, 2014 May 08; 35(8). PMID: 24801904
Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases.
Nolan Priedigkeit, Rebecca J Watters, +10 authors, Adrian V Lee.
JCI Insight, 2017 Sep 08; 2(17). PMID: 28878133    Free PMC article.
The landscape of chromosomal aberrations in breast cancer mouse models reveals driver-specific routes to tumorigenesis.
Uri Ben-David, Gavin Ha, +4 authors, Todd R Golub.
Nat Commun, 2016 Jul 05; 7. PMID: 27374210    Free PMC article.
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.
Katherine E Hutchinson, Susan E Yost, +8 authors, Yuan Yuan.
Clin Cancer Res, 2019 Oct 16; 26(3). PMID: 31611282
Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice.
Yunsik Choi, Sanghyuk Lee, +3 authors, Charles Lee.
Exp Mol Med, 2018 Aug 10; 50(8). PMID: 30089794    Free PMC article.
Molecular profiling of patient-derived breast cancer xenografts.
Fabien Reyal, Charlotte Guyader, +15 authors, Elisabetta Marangoni.
Breast Cancer Res, 2012 Jan 18; 14(1). PMID: 22247967    Free PMC article.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
Gunter von Minckwitz, Chiun-Sheng Huang, +27 authors, KATHERINE Investigators.
N Engl J Med, 2018 Dec 06; 380(7). PMID: 30516102
Highly Cited.
Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
E S Sokol, Y X Feng, +12 authors, R J Hartmaier.
Ann Oncol, 2018 Nov 14; 30(1). PMID: 30423024    Free PMC article.
A microengineered pathophysiological model of early-stage breast cancer.
Yoonseok Choi, Eunjeh Hyun, +7 authors, Dongeun Huh.
Lab Chip, 2015 Jul 15; 15(16). PMID: 26158500    Free PMC article.
HER2 and Breast Cancer - A Phenomenal Success Story.
Daniel F Hayes.
N Engl J Med, 2019 Sep 11; 381(13). PMID: 31502769
Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study.
Shin-Ae Kang, Jye Swei Guan, +12 authors, Yoon Pin Lim.
Clin Cancer Res, 2018 Dec 30; 25(8). PMID: 30593516
Breast tumour organoids: promising models for the genomic and functional characterisation of breast cancer.
Charlotte Roelofs, Frédéric Hollande, +2 authors, Delphine Merino.
Biochem Soc Trans, 2019 Jan 11; 47(1). PMID: 30626705
Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer.
Olivia K Provance, Joan Lewis-Wambi.
Breast Cancer Res, 2019 May 08; 21(1). PMID: 31060575    Free PMC article.
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
Sadhna R Vora, Dejan Juric, +17 authors, Jeffrey A Engelman.
Cancer Cell, 2014 Jul 09; 26(1). PMID: 25002028    Free PMC article.
Highly Cited.
CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
Hee-Joo Choi, Sora Jin, +12 authors, Gu Kong.
EMBO Rep, 2019 Aug 31; 20(10). PMID: 31468695    Free PMC article.
PIK3CA mutations are common in lobular carcinoma in situ, but are not a biomarker of progression.
Vandna Shah, Salpie Nowinski, +9 authors, Elinor J Sawyer.
Breast Cancer Res, 2017 Jan 18; 19(1). PMID: 28095868    Free PMC article.
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Yeon Hee Park, Tae-Yong Kim, +19 authors, Korean Cancer Study Group (KCSG).
Lancet Oncol, 2019 Nov 02; 20(12). PMID: 31668850
A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity.
Norman Sachs, Joep de Ligt, +28 authors, Hans Clevers.
Cell, 2017 Dec 12; 172(1-2). PMID: 29224780
Highly Cited.
A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Florence Coussy, Leanne de Koning, +27 authors, Elisabetta Marangoni.
Int J Cancer, 2019 Mar 13; 145(7). PMID: 30859564
Clonal relationships between lobular carcinoma in situ and other breast malignancies.
Colin B Begg, Irina Ostrovnaya, +9 authors, Tari A King.
Breast Cancer Res, 2016 Jun 24; 18(1). PMID: 27334989    Free PMC article.
Genomic Evolution of Breast Cancer Metastasis and Relapse.
Lucy R Yates, Stian Knappskog, +27 authors, Peter J Campbell.
Cancer Cell, 2017 Aug 16; 32(2). PMID: 28810143    Free PMC article.
Highly Cited.
Tumour evolution inferred by single-cell sequencing.
Nicholas Navin, Jude Kendall, +12 authors, Michael Wigler.
Nature, 2011 Mar 15; 472(7341). PMID: 21399628    Free PMC article.
Highly Cited.
Profiling human breast epithelial cells using single cell RNA sequencing identifies cell diversity.
Quy H Nguyen, Nicholas Pervolarakis, +14 authors, Kai Kessenbrock.
Nat Commun, 2018 May 26; 9(1). PMID: 29795293    Free PMC article.
Highly Cited.
Subclonal diversification of primary breast cancer revealed by multiregion sequencing.
Lucy R Yates, Moritz Gerstung, +35 authors, Peter J Campbell.
Nat Med, 2015 Jun 23; 21(7). PMID: 26099045    Free PMC article.
Highly Cited.
Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer.
Xuexin He, Jiali Ji, +3 authors, Sai-Ching Jim Yeung.
Clin Cancer Res, 2019 Sep 14; 25(24). PMID: 31515457
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.
M V Dieci, C Criscitiello, +8 authors, F Andre.
Ann Oncol, 2014 Jan 10; 25(3). PMID: 24401929    Free PMC article.
Highly Cited.
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.
Rachael Natrajan, Paul M Wilkerson, +24 authors, Jorge S Reis-Filho.
J Pathol, 2014 Jan 08; 232(5). PMID: 24395524    Free PMC article.
Clonal evolution in breast cancer revealed by single nucleus genome sequencing.
Yong Wang, Jill Waters, +13 authors, Nicholas E Navin.
Nature, 2014 Aug 01; 512(7513). PMID: 25079324    Free PMC article.
Highly Cited.
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis.
Yixiao Feng, Mia Spezia, +15 authors, Guosheng Ren.
Genes Dis, 2018 Sep 28; 5(2). PMID: 30258937    Free PMC article.
Highly Cited. Review.
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma.
Matthew Maurer, Tao Su, +26 authors, Ramon Parsons.
Cancer Res, 2009 Jul 16; 69(15). PMID: 19602588    Free PMC article.
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Bryan T Hennessy, Ana-Maria Gonzalez-Angulo, +24 authors, Gordon B Mills.
Cancer Res, 2009 May 14; 69(10). PMID: 19435916    Free PMC article.
Highly Cited.
Cell differentiation by extracellular matrix components.
R J Blaschke, A R Howlett, +2 authors, M J Bissell.
Methods Enzymol, 1994 Jan 01; 245. PMID: 7760750
Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer.
Joanna Achinger-Kawecka, Fatima Valdes-Mora, +16 authors, Susan J Clark.
Nat Commun, 2020 Jan 18; 11(1). PMID: 31949157    Free PMC article.
Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States.
Rita Caldeira, Mark Scazafave.
Oncol Ther, 2016 Jan 01; 4(2). PMID: 28261649    Free PMC article.
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Dejan Juric, Jordi Rodon, +16 authors, José Baselga.
J Clin Oncol, 2018 Feb 06; 36(13). PMID: 29401002    Free PMC article.
Highly Cited.
Wnt signaling in cancer.
T Zhan, N Rindtorff, M Boutros.
Oncogene, 2016 Sep 13; 36(11). PMID: 27617575    Free PMC article.
Highly Cited. Review.
Pan-cancer patterns of somatic copy number alteration.
Travis I Zack, Stephen E Schumacher, +15 authors, Rameen Beroukhim.
Nat Genet, 2013 Sep 28; 45(10). PMID: 24071852    Free PMC article.
Highly Cited.
The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium.
Justin M Balko, Todd W Miller, +10 authors, Rebecca S Cook.
Proc Natl Acad Sci U S A, 2011 Dec 20; 109(1). PMID: 22178756    Free PMC article.
Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort.
A Mukherjee, R Russell, +9 authors, E Provenzano.
NPJ Breast Cancer, 2018 Mar 14; 4. PMID: 29532008    Free PMC article.
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
Thomas Karn, Tingting Jiang, +7 authors, Lajos Pusztai.
JAMA Oncol, 2017 Jul 28; 3(12). PMID: 28750120    Free PMC article.
Recent Advances in Comprehending the Signaling Pathways Involved in the Progression of Breast Cancer.
Andrea Nicolini, Paola Ferrari, Lucrezia Diodati, Angelo Carpi.
Int J Mol Sci, 2017 Nov 04; 18(11). PMID: 29099748    Free PMC article.
Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer.
Stefano Annunziato, Marco Barazas, Sven Rottenberg, Jos Jonkers.
Cold Spring Harb Symp Quant Biol, 2016 Nov 07; 81. PMID: 27815543
Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma.
Sjors M Kas, Julian R de Ruiter, +13 authors, Jos Jonkers.
Nat Genet, 2017 Jun 27; 49(8). PMID: 28650484
Palbociclib and Letrozole in Advanced Breast Cancer.
Richard S Finn, Miguel Martin, +12 authors, Dennis J Slamon.
N Engl J Med, 2016 Dec 14; 375(20). PMID: 27959613
Highly Cited.
Early dissemination seeds metastasis in breast cancer.
Hedayatollah Hosseini, Milan M S Obradović, +24 authors, Christoph A Klein.
Nature, 2016 Dec 16; 540(7634). PMID: 27974799    Free PMC article.
Highly Cited.
Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.
Jeff C Liu, Veronique Voisin, +6 authors, Eldad Zacksenhaus.
Proc Natl Acad Sci U S A, 2012 Mar 31; 109(15). PMID: 22460789    Free PMC article.
Establishment and Morphological Characterization of Patient-Derived Organoids from Breast Cancer.
S Mazzucchelli, F Piccotti, +8 authors, F Corsi.
Biol Proced Online, 2019 Jun 22; 21. PMID: 31223292    Free PMC article.
Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
Maiko Okano, Masanori Oshi, +6 authors, Kazuaki Takabe.
Int J Mol Sci, 2019 Jun 04; 20(11). PMID: 31151151    Free PMC article.
Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy.
Laura Creevey, Rachel Bleach, +6 authors, Marie McIlroy.
Mol Cancer Ther, 2019 Jul 11; 18(10). PMID: 31289138
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Luca Gianni, Giancarlo Bisagni, +8 authors, Giuseppe Viale.
Lancet Oncol, 2018 Jan 13; 19(2). PMID: 29326029
Highly Cited.
Genome-driven integrated classification of breast cancer validated in over 7,500 samples.
H Raza Ali, Oscar M Rueda, +4 authors, Carlos Caldas.
Genome Biol, 2014 Aug 29; 15(8). PMID: 25164602    Free PMC article.
Highly Cited.
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Joseph A Sparano, Robert J Gray, +27 authors, George W Sledge.
N Engl J Med, 2019 Jun 04; 380(25). PMID: 31157962    Free PMC article.
Highly Cited.
Genomic landscape of ductal carcinoma in situ and association with progression.
Chieh-Yu Lin, Sujay Vennam, +10 authors, Robert B West.
Breast Cancer Res Treat, 2019 Aug 20; 178(2). PMID: 31420779    Free PMC article.
Mammary adipose stromal cells derived from obese women reduce sensitivity to the aromatase inhibitor anastrazole in an organotypic breast model.
Molly M Morgan, Lisa M Arendt, +2 authors, Brian P Johnson.
FASEB J, 2019 Apr 20; 33(7). PMID: 31002529    Free PMC article.
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Lisa A Carey, Donald A Berry, +15 authors, Clifford A Hudis.
J Clin Oncol, 2015 Nov 04; 34(6). PMID: 26527775    Free PMC article.
Highly Cited.
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Matthew J Ellis, Li Ding, +56 authors, Elaine R Mardis.
Nature, 2012 Jun 23; 486(7403). PMID: 22722193    Free PMC article.
Highly Cited.
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, +11 authors, Pierfranco Conte.
N Engl J Med, 2017 Jun 06; 377(6). PMID: 28578601
Highly Cited.
Micropapillary variant of mucinous breast carcinoma: A distinct subtype.
Katrina Collins, Andrew Ricci.
Breast J, 2017 Oct 25; 24(3). PMID: 29063656
The clonal and mutational evolution spectrum of primary triple-negative breast cancers.
Sohrab P Shah, Andrew Roth, +56 authors, Samuel Aparicio.
Nature, 2012 Apr 13; 486(7403). PMID: 22495314    Free PMC article.
Highly Cited.
Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type.
Magali Lacroix-Triki, Paula H Suarez, +7 authors, Jorge S Reis-Filho.
J Pathol, 2010 Sep 04; 222(3). PMID: 20815046
Molecular subtyping of male breast cancer by immunohistochemistry.
Robert Kornegoor, Anoek H J Verschuur-Maes, +6 authors, Paul J van Diest.
Mod Pathol, 2011 Nov 08; 25(3). PMID: 22056953
BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.
Louise Walsh, Kathryn E Haley, +19 authors, Tríona Ní Chonghaile.
Clin Cancer Res, 2019 Aug 15; 25(23). PMID: 31409615
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Cristina Saura, Dominik Hlauschek, +23 authors, Evandro de Azambuja.
Lancet Oncol, 2019 Aug 14; 20(9). PMID: 31402321
Highly Cited.
Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis.
Haixia Chen, Jianming Wu, +5 authors, Xianzhu Li.
Front Pharmacol, 2018 Sep 07; 9. PMID: 30186165    Free PMC article.
Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Xi-Yu Liu, Ding Ma, +4 authors, Zhi-Ming Shao.
Theranostics, 2019 Jan 08; 8(22). PMID: 30613307    Free PMC article.
Clinicopathological and epidemiological significance of breast cancer subtype reclassification based on p53 immunohistochemical expression.
Mustapha Abubakar, Changyuan Guo, +9 authors, Xiaohong R Yang.
NPJ Breast Cancer, 2019 Aug 03; 5. PMID: 31372496    Free PMC article.
Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.
Max D Wellenstein, Seth B Coffelt, +17 authors, Karin E de Visser.
Nature, 2019 Aug 02; 572(7770). PMID: 31367040    Free PMC article.
Highly Cited.
β-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
Tung Bui, Babette Schade, +3 authors, William J Muller.
Proc Natl Acad Sci U S A, 2017 Jan 18; 114(5). PMID: 28096336    Free PMC article.
DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-Positive Breast Cancer Following Endocrine Therapy.
Daniel S Peiffer, Debra Wyatt, +5 authors, Clodia Osipo.
Cancer Res, 2019 Aug 08; 79(19). PMID: 31387918    Free PMC article.
Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study.
Fei Ma, Quchang Ouyang, +11 authors, Binghe Xu.
J Clin Oncol, 2019 Aug 21; 37(29). PMID: 31430226
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Kenji Tamura, Junji Tsurutani, +14 authors, Shanu Modi.
Lancet Oncol, 2019 May 03; 20(6). PMID: 31047803
Highly Cited.
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
Sarat Chandarlapaty, Rita A Sakr, +8 authors, Tari A King.
Clin Cancer Res, 2012 Oct 25; 18(24). PMID: 23092874    Free PMC article.
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Henne Holstege, Simon A Joosse, +3 authors, Jos Jonkers.
Cancer Res, 2009 Apr 02; 69(8). PMID: 19336573
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.
Carsten Denkert, Gunter von Minckwitz, +27 authors, Sibylle Loibl.
J Clin Oncol, 2014 Dec 24; 33(9). PMID: 25534375
Highly Cited.
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
Xian Chen, Kwang-Huei Low, +15 authors, Khandan Keyomarsi.
Clin Cancer Res, 2018 Sep 06; 24(24). PMID: 30181387    Free PMC article.
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Emad A Rakha, Somaia E Elsheikh, +12 authors, Ian O Ellis.
Clin Cancer Res, 2009 Mar 26; 15(7). PMID: 19318481
Highly Cited.
Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, +72 authors, Michael R Stratton.
Nature, 2013 Aug 16; 500(7463). PMID: 23945592    Free PMC article.
Highly Cited.
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
Paz Polak, Jaegil Kim, +25 authors, Gad Getz.
Nat Genet, 2017 Aug 22; 49(10). PMID: 28825726    Free PMC article.
Highly Cited.
Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death.
Haley Hieronymus, Rajmohan Murali, +12 authors, Charles L Sawyers.
Elife, 2018 Sep 05; 7. PMID: 30178746    Free PMC article.
Highly Cited.
Lineage-Restricted Mammary Stem Cells Sustain the Development, Homeostasis, and Regeneration of the Estrogen Receptor Positive Lineage.
Alexandra Van Keymeulen, Marco Fioramonti, +3 authors, Cédric Blanpain.
Cell Rep, 2017 Aug 17; 20(7). PMID: 28813665    Free PMC article.
Reconstruction of functionally normal and malignant human breast tissues in mice.
Charlotte Kuperwasser, Tony Chavarria, +5 authors, Robert A Weinberg.
Proc Natl Acad Sci U S A, 2004 Mar 31; 101(14). PMID: 15051869    Free PMC article.
Highly Cited.
Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer.
Shuyan Sheng, Ye Xu, +9 authors, Yuntao Xie.
Int J Cancer, 2019 May 24; 146(2). PMID: 31119730
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.
C T Guy, R D Cardiff, W J Muller.
Mol Cell Biol, 1992 Mar 01; 12(3). PMID: 1312220    Free PMC article.
Highly Cited.
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Mario Campone, Seock-Ah Im, +20 authors, José Baselga.
Eur J Cancer, 2018 Sep 22; 103. PMID: 30241001
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Rashmi K Murthy, Sherene Loi, +29 authors, Eric P Winer.
N Engl J Med, 2019 Dec 12; 382(7). PMID: 31825569
Highly Cited.
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes.
Joseph H Taube, Jason I Herschkowitz, +13 authors, Sendurai A Mani.
Proc Natl Acad Sci U S A, 2010 Aug 18; 107(35). PMID: 20713713    Free PMC article.
Highly Cited.
Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
Kate Packwood, Guy Martland, +12 authors, Diana M Eccles.
J Pathol Clin Res, 2019 May 02; 5(3). PMID: 31041842    Free PMC article.
Whole exome sequencing of rare aggressive breast cancer histologies.
Maria Vittoria Dieci, Veronika Smutná, +14 authors, Celine Lefebvre.
Breast Cancer Res Treat, 2016 Feb 26; 156(1). PMID: 26907767
High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features.
Juan Manuel Rosa-Rosa, Tamara Caniego-Casas, +8 authors, José Palacios.
Cancers (Basel), 2019 Jan 16; 11(1). PMID: 30641862    Free PMC article.
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
G N Hortobagyi, S M Stemmer, +18 authors, J O'Shaughnessy.
Ann Oncol, 2018 May 03; 29(7). PMID: 29718092
Highly Cited.
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.
Sarah Croessmann, Luigi Formisano, +13 authors, Carlos L Arteaga.
Clin Cancer Res, 2018 Oct 14; 25(1). PMID: 30314968    Free PMC article.
Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers.
Allison S Cleary, Travis L Leonard, Shelley A Gestl, Edward J Gunther.
Nature, 2014 Apr 04; 508(7494). PMID: 24695311    Free PMC article.
Highly Cited.
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
J H Park, S F Jonas, +11 authors, S Michiels.
Ann Oncol, 2019 Oct 01; 30(12). PMID: 31566659
Highly Cited.
Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications.
Amy Ellen McCart Reed, Emarene Kalaw, +36 authors, Sunil R Lakhani.
J Pathol, 2018 Oct 24; 247(2). PMID: 30350370
Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors.
Dominique S Meyer, Heike Brinkhaus, +3 authors, Mohamed Bentires-Alj.
Cancer Res, 2011 Apr 13; 71(13). PMID: 21482677
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Therapeutic targeting of BRCA1 and TP53 mutant breast cancer through mutant p53 reactivation.
Bing Na, Xin Yu, +10 authors, Darren R Carpizo.
NPJ Breast Cancer, 2019 Apr 18; 5. PMID: 30993195    Free PMC article.
Intra-tumor molecular heterogeneity in breast cancer: definitions of measures and association with distant recurrence-free survival.
Ashirbani Saha, Michael R Harowicz, +5 authors, Maciej A Mazurowski.
Breast Cancer Res Treat, 2018 Jul 12; 172(1). PMID: 29992418    Free PMC article.
Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment.
Nathan A Ungerleider, Sonia G Rao, +4 authors, James G Jackson.
Breast Cancer Res, 2018 Oct 05; 20(1). PMID: 30285883    Free PMC article.
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis.
Laura M Spring, Geoffrey Fell, +10 authors, Aditya Bardia.
Clin Cancer Res, 2020 Feb 13; 26(12). PMID: 32046998    Free PMC article.
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.
Alexandra Van Keymeulen, May Yin Lee, +10 authors, Cédric Blanpain.
Nature, 2015 Aug 13; 525(7567). PMID: 26266985
Highly Cited.
The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.
Arian Lundberg, Linda S Lindström, +8 authors, Nicholas P Tobin.
Breast Cancer Res, 2019 Mar 02; 21(1). PMID: 30819233    Free PMC article.
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Aleix Prat, Maggie C U Cheang, +9 authors, Stephen Johnston.
JAMA Oncol, 2016 Jun 10; 2(10). PMID: 27281556
Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland.
Stefano Annunziato, Sjors M Kas, +14 authors, Jos Jonkers.
Genes Dev, 2016 Jun 25; 30(12). PMID: 27340177    Free PMC article.
Highly Cited.
Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts.
Guochun Zhang, Yulei Wang, +20 authors, Ning Liao.
Ann Transl Med, 2019 Jun 07; 7(8). PMID: 31168460    Free PMC article.
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Justin M Balko, Jennifer M Giltnane, +24 authors, Carlos L Arteaga.
Cancer Discov, 2013 Dec 21; 4(2). PMID: 24356096    Free PMC article.
Highly Cited.
Slug and Sox9 cooperatively determine the mammary stem cell state.
Wenjun Guo, Zuzana Keckesova, +11 authors, Robert A Weinberg.
Cell, 2012 Mar 06; 148(5). PMID: 22385965    Free PMC article.
Highly Cited.
Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.
Damir Varešlija, Nolan Priedigkeit, +26 authors, Leonie S Young.
J Natl Cancer Inst, 2018 Jul 03; 111(4). PMID: 29961873    Free PMC article.
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.
Pixu Liu, Hailing Cheng, +13 authors, Jean J Zhao.
Nat Med, 2011 Aug 09; 17(9). PMID: 21822287    Free PMC article.
Highly Cited.
Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.
A C Picornell, I Echavarria, +17 authors, M Martin.
BMC Genomics, 2019 Jun 05; 20(1). PMID: 31159741    Free PMC article.
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.
Richard D Baird, Annelot G J van Rossum, +25 authors, Sabine C Linn.
Clin Cancer Res, 2019 Aug 24; 25(22). PMID: 31439579
A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors.
Lee S Rosen, Robert Wesolowski, +5 authors, Anthony W Tolcher.
Invest New Drugs, 2019 Mar 20; 38(1). PMID: 30887250
Activation of KRAS promotes the mesenchymal features of basal-type breast cancer.
Rae-Kwon Kim, Yongjoon Suh, +5 authors, Su-Jae Lee.
Exp Mol Med, 2015 Jan 31; 47. PMID: 25633745    Free PMC article.
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.
Mark Kriegsmann, Volker Endris, +8 authors, Wilko Weichert.
Oncotarget, 2014 Oct 10; 5(20). PMID: 25296970    Free PMC article.
Genome Sequencing during a Patient's Journey through Cancer.
Jyoti Nangalia, Peter J Campbell.
N Engl J Med, 2019 Nov 28; 381(22). PMID: 31774959
Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer.
Bastien Nguyen, Isabelle Veys, +8 authors, Christine Desmedt.
J Natl Cancer Inst, 2019 Feb 23; 111(7). PMID: 30789657
Inflammatory breast cancer biology: the tumour microenvironment is key.
Bora Lim, Wendy A Woodward, +2 authors, Naoto T Ueno.
Nat Rev Cancer, 2018 Apr 29; 18(8). PMID: 29703913
Highly Cited. Review.
Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner.
Joshua Ogony, Hye Joung Choi, +2 authors, Joan Lewis-Wambi.
Breast Cancer Res, 2016 Feb 22; 18(1). PMID: 26897526    Free PMC article.
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Rita Nanda, Minetta C Liu, +41 authors, Laura J Esserman.
JAMA Oncol, 2020 Feb 14; 6(5). PMID: 32053137    Free PMC article.
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Peter Schmid, Jacinta Abraham, +26 authors, Nicholas C Turner.
J Clin Oncol, 2019 Dec 17; 38(5). PMID: 31841354
Highly Cited.
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
George W Sledge, Masakazu Toi, +16 authors, Antonio Llombart-Cussac.
JAMA Oncol, 2019 Sep 30;. PMID: 31563959    Free PMC article.
Highly Cited.
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.
Alex Pearson, Paula Proszek, +23 authors, Nicholas C Turner.
Clin Cancer Res, 2019 Oct 09; 26(3). PMID: 31591187
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.
Stephen Johnston, Miguel Martin, +10 authors, Matthew P Goetz.
NPJ Breast Cancer, 2019 Jan 25; 5. PMID: 30675515    Free PMC article.
Highly Cited.
Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma.
M J Thornton, H V Williamson, +7 authors, O M Fayanju.
Ann Surg Oncol, 2019 Jul 26; 26(10). PMID: 31342392    Free PMC article.
DLG5 suppresses breast cancer stem cell-like characteristics to restore tamoxifen sensitivity by inhibiting TAZ expression.
Jie Liu, Juan Li, +5 authors, Peijun Liu.
J Cell Mol Med, 2018 Nov 20; 23(1). PMID: 30450766    Free PMC article.
Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.
Darren K Patten, Giacomo Corleone, +17 authors, Luca Magnani.
Nat Med, 2018 Jul 25; 24(9). PMID: 30038216    Free PMC article.
Oncogenic Signaling Pathways in The Cancer Genome Atlas.
Francisco Sanchez-Vega, Marco Mina, +52 authors, Nikolaus Schultz.
Cell, 2018 Apr 07; 173(2). PMID: 29625050    Free PMC article.
Highly Cited.
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution.
Sohrab P Shah, Ryan D Morin, +27 authors, Samuel Aparicio.
Nature, 2009 Oct 09; 461(7265). PMID: 19812674
Highly Cited.
Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Takashi Takeshita, Yutaka Yamamoto, +4 authors, Hirotaka Iwase.
Mol Cancer, 2018 Feb 28; 17(1). PMID: 29482551    Free PMC article.
Moving Breast Cancer Therapy up a Notch.
Erik W J Mollen, Jonathan Ient, +4 authors, Marc A G G Vooijs.
Front Oncol, 2018 Dec 06; 8. PMID: 30515368    Free PMC article.
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Angelo Di Leo, Stephen Johnston, +18 authors, Thomas Bachelot.
Lancet Oncol, 2017 Dec 11; 19(1). PMID: 29223745
Highly Cited.
Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110α/PIK3CA but not by HER2 or mutant AKT1.
F M Berglund, N R Weerasinghe, +3 authors, N R Leslie.
Oncogene, 2012 Oct 23; 32(37). PMID: 23085752    Free PMC article.
Molecular stratification within triple-negative breast cancer subtypes.
Dong-Yu Wang, Zhe Jiang, +2 authors, Eldad Zacksenhaus.
Sci Rep, 2019 Dec 15; 9(1). PMID: 31836816    Free PMC article.
The life history of 21 breast cancers.
Serena Nik-Zainal, Peter Van Loo, +47 authors, Breast Cancer Working Group of the International Cancer Genome Consortium.
Cell, 2012 May 23; 149(5). PMID: 22608083    Free PMC article.
Highly Cited.
Clonal analysis of Notch1-expressing cells reveals the existence of unipotent stem cells that retain long-term plasticity in the embryonic mammary gland.
Anna M Lilja, Veronica Rodilla, +7 authors, Silvia Fre.
Nat Cell Biol, 2018 May 23; 20(6). PMID: 29784917    Free PMC article.
Highly Cited.
Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
F S Kenny, R Hui, +5 authors, J F Robertson.
Clin Cancer Res, 1999 Sep 03; 5(8). PMID: 10473088
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.
Magali Michaut, Suet-Feung Chin, +43 authors, Rene Bernards.
Sci Rep, 2016 Jan 06; 6. PMID: 26729235    Free PMC article.
Highly Cited.
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Dennis J Slamon, Patrick Neven, +18 authors, Guy Jerusalem.
J Clin Oncol, 2018 Jun 05; 36(24). PMID: 29860922
Highly Cited.
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value.
Federica Miglietta, Gaia Griguolo, Valentina Guarneri, Maria Vittoria Dieci.
Oncologist, 2019 Aug 25; 24(11). PMID: 31444294    Free PMC article.
Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors.
M Brandão, R Caparica, D Eiger, E de Azambuja.
Ann Oncol, 2019 Dec 21; 30(Suppl_10). PMID: 31859350    Free PMC article.
Organotypic microfluidic breast cancer model reveals starvation-induced spatial-temporal metabolic adaptations.
Jose M Ayuso, Amani Gillette, +8 authors, David J Beebe.
EBioMedicine, 2018 Nov 30; 37. PMID: 30482722    Free PMC article.
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.
Aleix Prat, Tomás Pascual, +32 authors, Mothaffar F Rimawi.
J Natl Cancer Inst, 2019 May 01; 112(1). PMID: 31037288    Free PMC article.
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), C Davies, +11 authors, R Peto.
Lancet, 2011 Aug 02; 378(9793). PMID: 21802721    Free PMC article.
Highly Cited.
A Quiescent Bcl11b High Stem Cell Population Is Required for Maintenance of the Mammary Gland.
Shang Cai, Tomer Kalisky, +18 authors, Michael F Clarke.
Cell Stem Cell, 2017 Jan 04; 20(2). PMID: 28041896    Free PMC article.
Xenograft and organoid model systems in cancer research.
Margit Bleijs, Marc van de Wetering, Hans Clevers, Jarno Drost.
EMBO J, 2019 Jul 10; 38(15). PMID: 31282586    Free PMC article.
Highly Cited. Review.
Invasive lobular carcinoma: response to neoadjuvant letrozole therapy.
J Michael Dixon, Lorna Renshaw, Jonathan Dixon, Jeremy Thomas.
Breast Cancer Res Treat, 2011 Aug 27; 130(3). PMID: 21870129
A Review of the Hereditary Component of Triple Negative Breast Cancer: High- and Moderate-Penetrance Breast Cancer Genes, Low-Penetrance Loci, and the Role of Nontraditional Genetic Elements.
Darrell L Ellsworth, Clesson E Turner, Rachel E Ellsworth.
J Oncol, 2019 Aug 06; 2019. PMID: 31379942    Free PMC article.
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer.
Liping Ye, Chuyong Lin, +16 authors, Libing Song.
EMBO Mol Med, 2019 Oct 28; 11(12). PMID: 31657150    Free PMC article.
A "NOTCH" Deeper into the Epithelial-To-Mesenchymal Transition (EMT) Program in Breast Cancer.
Rohan Kar, Niraj Kumar Jha, +7 authors, Parma Nand.
Genes (Basel), 2019 Nov 27; 10(12). PMID: 31766724    Free PMC article.
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, +4 authors, Jennifer A Pietenpol.
J Clin Invest, 2011 Jun 03; 121(7). PMID: 21633166    Free PMC article.
Highly Cited.
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.
Christina Curtis, Sohrab P Shah, +29 authors, Samuel Aparicio.
Nature, 2012 Apr 24; 486(7403). PMID: 22522925    Free PMC article.
Highly Cited.
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes.
Hiroko Masuda, Keith A Baggerly, +9 authors, Naoto T Ueno.
Clin Cancer Res, 2013 Aug 21; 19(19). PMID: 23948975    Free PMC article.
Highly Cited.
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
George W Sledge, Masakazu Toi, +15 authors, Antonio Llombart-Cussac.
J Clin Oncol, 2017 Jun 06; 35(25). PMID: 28580882
Highly Cited.
Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma.
C Gamallo, J Palacios, +4 authors, A Cano.
Am J Pathol, 1993 Apr 01; 142(4). PMID: 7682767    Free PMC article.
Highly Cited.
Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis.
N Wu, F Fu, +3 authors, C Wang.
Clin Transl Oncol, 2019 Jun 22; 22(4). PMID: 31222450
Systematic Review.
Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Yingying Shen, Wei Zhang, +11 authors, Xuyu Zu.
Int J Cancer, 2018 Oct 06; 144(3). PMID: 30289981
Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype.
Gyu-Beom Jang, Ji-Young Kim, +5 authors, Jeong-Seok Nam.
Sci Rep, 2015 Jul 24; 5. PMID: 26202299    Free PMC article.
Highly Cited.
Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
Jeffrey S Ross, Sunil Badve, +11 authors, Philip J Stephens.
Arch Pathol Lab Med, 2015 May 01; 139(5). PMID: 25927147
IRS2 mutations linked to invasion in pleomorphic invasive lobular carcinoma.
Sha Zhu, B Marie Ward, +8 authors, Leslie M Shaw.
JCI Insight, 2018 Apr 20; 3(8). PMID: 29669935    Free PMC article.
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Silvia Darb-Esfahani, Carsten Denkert, +20 authors, Sibylle Loibl.
Oncotarget, 2016 Sep 10; 7(42). PMID: 27611952    Free PMC article.
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade.
Fara Brasó-Maristany, Gaia Griguolo, +25 authors, Aleix Prat.
Nat Commun, 2020 Jan 22; 11(1). PMID: 31959756    Free PMC article.
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, +15 authors, Joanne L Blum.
N Engl J Med, 2018 Aug 16; 379(8). PMID: 30110579
Highly Cited.
Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.
Suping Zhang, Han Zhang, +15 authors, Thomas J Kipps.
Proc Natl Acad Sci U S A, 2019 Jan 10; 116(4). PMID: 30622177    Free PMC article.
Highly Cited.
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer.
Giovanni Ciriello, Michael L Gatza, +30 authors, Charles M Perou.
Cell, 2015 Oct 10; 163(2). PMID: 26451490    Free PMC article.
Highly Cited.
β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.
Babette Schade, Robert Lesurf, +11 authors, William J Muller.
Cancer Res, 2013 May 31; 73(14). PMID: 23720052
Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer.
Alvaro Avivar-Valderas, Robert McEwen, +6 authors, Francisco Cruzalegui.
Oncotarget, 2018 May 17; 9(30). PMID: 29765551    Free PMC article.
Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
Li Chen, Liu Yang, +13 authors, Zhi-Ming Shao.
Nat Commun, 2018 Apr 11; 9(1). PMID: 29636477    Free PMC article.
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.
Guotai Xu, Sagar Chhangawala, +28 authors, Eneda Toska.
Nat Genet, 2020 Jan 15; 52(2). PMID: 31932695    Free PMC article.
Dramatic dysbalancing of the Wnt pathway in breast cancers.
Alexey Koval, Vladimir L Katanaev.
Sci Rep, 2018 May 11; 8(1). PMID: 29743726    Free PMC article.
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies.
Utthara Nayar, Ofir Cohen, +15 authors, Nikhil Wagle.
Nat Genet, 2018 Dec 12; 51(2). PMID: 30531871
Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.
Sibylle Loibl, Denise Treue, +21 authors, Carsten Denkert.
Clin Cancer Res, 2019 Apr 14; 25(13). PMID: 30979740
Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.
Tingting Jiang, Weiwei Shi, +8 authors, Christos Hatzis.
PLoS Med, 2016 Dec 14; 13(12). PMID: 27959926    Free PMC article.
Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
Christoph Engel, Kerstin Rhiem, +26 authors, German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC).
BMC Cancer, 2018 Mar 09; 18(1). PMID: 29514593    Free PMC article.
The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study.
Serena Di Cosimo, Tiziana Triulzi, +18 authors, Elda Tagliabue.
Eur J Cancer, 2019 Jul 10; 118. PMID: 31284184
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Sung-Bae Kim, Rebecca Dent, +13 authors, LOTUS investigators.
Lancet Oncol, 2017 Aug 13; 18(10). PMID: 28800861    Free PMC article.
Highly Cited.
Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
Yi Xiao, Ding Ma, +18 authors, AME Breast Cancer Collaborative Group.
Clin Cancer Res, 2019 Mar 07; 25(16). PMID: 30837276
Highly Cited.
Targeted therapeutic options and future perspectives for HER2-positive breast cancer.
Jiani Wang, Binghe Xu.
Signal Transduct Target Ther, 2019 Oct 23; 4. PMID: 31637013    Free PMC article.
Mechanism of early dissemination and metastasis in Her2+ mammary cancer.
Kathryn L Harper, Maria Soledad Sosa, +11 authors, Julio A Aguirre-Ghiso.
Nature, 2016 Dec 16; 540(7634). PMID: 27974798    Free PMC article.
Highly Cited.
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Helen Davies, Dominik Glodzik, +30 authors, Serena Nik-Zainal.
Nat Med, 2017 Mar 14; 23(4). PMID: 28288110    Free PMC article.
Highly Cited.
The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.
Hui Liu, Marcia N Paddock, +8 authors, Alex Toker.
Cancer Discov, 2020 Jun 10; 10(8). PMID: 32513774    Free PMC article.
Downregulation of Immortalization-Upregulated Protein Suppresses the Progression of Breast Cancer Cell Lines by Regulating Epithelial-Mesenchymal Transition.
Jialiang Wen, Lizhi Lin, +3 authors, Ouchen Wang.
Cancer Manag Res, 2020 Sep 29; 12. PMID: 32982454    Free PMC article.
A Complex and Evolutive Character: Two Face Aspects of ECM in Tumor Progression.
Margaux Sala, Manon Ros, Frédéric Saltel.
Front Oncol, 2020 Sep 29; 10. PMID: 32984031    Free PMC article.
Divergent organ-specific isogenic metastatic cell lines identified using multi-omics exhibit differential drug sensitivity.
Paul T Winnard, Farhad Vesuna, Sankar Muthukumar, Venu Raman.
PLoS One, 2020 Nov 17; 15(11). PMID: 33196681    Free PMC article.
Gene Expression Alterations Associated with Oleuropein-Induced Antiproliferative Effects and S-Phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells.
Samia S Messeha, Najla O Zarmouh, Abrar Asiri, Karam F A Soliman.
Nutrients, 2020 Dec 11; 12(12). PMID: 33297339    Free PMC article.